≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Alzheimer’s disease (undefined)

DOID Endpoint Browser

AD_U

Alzheimer's disease: A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — F009&G309
  • Cause of death: ICD-10 — F009&G309

2 out of 7 registries used, show all original rules.

517

4. Check minimum number of events

None

517

5. Include endpoints

None

517

6. Filter based on genotype QC (FinnGen only)

504

Control definitions (FinnGen only)

Control exclude
G6_ALZHEIMER

Extra metadata

First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 504 222 282
Unadjusted period prevalence (%) 0.11 0.08 0.13
Median age at first event (years) 80.37 82.22 78.91

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
517
Matched controls
5170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N06DX01
ATC
memantine; oral
39.8
307.7
281
150
G30.1
ICD-10 Finland
Alzheimer disease with late onset
119.4
307.7
273
48
N06DA02
ATC
donepezil; oral
40.4
307.7
252
119
F009, G309,
ICD-10 Finland
+∞
307.7
510
*
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
280.1
307.7
398
61
G30.9
ICD-10 Finland
Alzheimer disease, unspecified
993.6
307.7
314
8
F00.10*G30.1
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
72.8
258.8
143
27
N06DA03
ATC
rivastigmine; oral, transdermal
26.3
204.1
154
82
N05AX08
ATC
risperidone; systemic
11.8
159.9
211
286
G30.8
ICD-10 Finland
Other Alzheimer disease
62.9
118.0
66
12
F0019, G301,
ICD-10 Finland
+∞
110.5
102
*
F00.10
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
56.5
89.4
51
10
F00.9
ICD-10 Finland
Dementia in Alzheimer disease, unspecified
273.6
71.2
71
*
N05AH04
ATC
quetiapine; oral
6.3
70.4
144
297
N06DA04
ATC
galantamine; oral
15.2
67.6
62
46
G30.0
ICD-10 Finland
Alzheimer disease with early onset
+∞
62.8
59
*
F0009, G300,
ICD-10 Finland
+∞
58.5
55
*
F03
ICD-10 Finland
Unspecified dementia
5.2
57.4
147
366
F00.20*G30.8
ICD-10 Finland
Dementia in Alzheimer's disease, atypical or mixed type without additional symptoms
14.9
54.3
50
37
P70
ICPC
Dementia
9.4
49.1
62
74
F00.00*G30.0
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, presenile onset without additional symptoms
102.4
35.2
38
*
N06AB04
ATC
citalopram; systemic
3.0
26.9
159
669
N05BA04
ATC
oxazepam; oral
2.7
24.1
183
871
N03AG01
ATC
valproic acid; systemic, rectal
6.4
23.8
41
69
G30
ICD-10 Finland
Alzheimer disease
35.3
23.6
30
9
Z75.5
ICD-10 Finland
Holiday relief care
6.0
21.5
39
69
N05AH03
ATC
olanzapine; systemic
7.7
21.0
30
41
F0029, G308,
ICD-10 Finland
+∞
21.0
20
*
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.3
20.2
84
284
Z02.4
ICD-10 Finland
Examination for driving licence
0.1
19.7
7
659
N05AD03
ATC
melperone; systemic
4.8
18.6
44
99
N05AD01
ATC
haloperidol; systemic
3.8
15.9
51
145
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.5
14.2
52
161
N06AB10
ATC
escitalopram; oral
2.8
13.5
73
285
WYA20
NOMESCO Finland
Home visit
4.4
13.4
34
81
N05BA06
ATC
lorazepam; systemic, sublingual
3.2
12.6
52
174
F00.19
ICD-10 Finland
Dementia in Alzheimer's disease with late onset without information about additional symptoms
133.1
12.5
13
*
R53
ICD-10 Finland
Malaise and fatigue
2.1
12.3
166
966
S18
ICPC
Laceration/cut
0.3
12.0
42
1109
R41.0
ICD-10 Finland
Disorientation, unspecified
3.4
11.6
43
134
SPAT1251
SPAT
Organisation of medication
3.1
10.9
47
161
N02AJ06
ATC
codeine and paracetamol; systemic
0.2
10.7
15
680
A06AD11
ATC
lactulose; oral
1.9
10.7
171
1049
F0014, G301,
ICD-10 Finland
+∞
10.4
10
*
A98
ICPC
Health maint/preventive medicine
0.5
10.2
153
2309
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.4
9.6
35
108
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.2
9.4
37
120
N07AA05, ,
ATC
+∞
9.4
9
*
H81
ICPC
Excessive ear wax
0.2
9.4
12
580
F00.00
ICD-10 Finland
Primary degenerative dementia of the Alzheimer's type, presenile onset without additional symptoms
37.4
9.0
11
*
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
9.0
218
1505
N06AX11
ATC
mirtazapine; oral
1.9
8.9
148
911
EBA15
NOMESCO Finland
Extraction of multiple teeth
4.1
8.9
24
60
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
0.3
8.6
21
683
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.7
7.9
234
1694
E000001, ,
ATC
2.0
7.8
94
517
G91.2
ICD-10 Finland
Normal-pressure hydrocephalus
4.1
7.4
20
50
130
Kela drug reimbursment
Malignant tumour
0.2
7.1
8
354
Z71.8
ICD-10 Finland
Other specified counselling
0.3
7.1
17
563
B01AF02
ATC
apixaban; oral
0.2
7.0
11
468
H13
ICPC
Plugged feeling ear
0.3
7.0
19
587
P20
ICPC
Memory disturbance
1.9
7.0
94
537
C04AE01
ATC
ergoloid mesylates; systemic
4.1
6.9
19
48
K03.82
ICD-10 Finland
Split tooth for reasons other than trauma
0.1
6.9
*
228
M79.6
ICD-10 Finland
Pain in limb
0.4
6.9
45
932
SPAT1043
SPAT
Audiometry
0.2
6.7
7
326
DFF00
NOMESCO Finland
Pure tone audiometry
0.1
6.7
*
247
SPAT1153
SPAT
Removal of sutures
0.4
6.7
31
738
L17
ICPC
Foot/toe symptom/complaint
0.3
6.6
21
599
F51.0
ICD-10 Finland
Nonorganic insomnia
0.1
6.5
*
190
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
0.3
6.5
19
564
SPAT1245
SPAT
Provision of support and information to patient’s family members
2.4
6.4
44
193
M25.5
ICD-10 Finland
Pain in joint
0.3
6.3
13
469
H02
ICPC
Hearing complaint
0.2
6.3
10
423
F00.20
ICD-10 Finland
Dementia in Alzheimer's disease, atypical or mixed type without additional symptoms
18.3
6.3
9
5
F009, G308,
ICD-10 Finland
+∞
6.3
6
*
3310A
ICD-9 Finland
Other cerebral degenerations, Alzheimer's disease
+∞
6.3
6
*
R23.8
ICD-10 Finland
Other and unspecified skin changes
0.2
6.2
10
419
F05.1
ICD-10 Finland
Delirium superimposed on dementia
8.7
6.1
12
14
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
0.1
6.0
*
229

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
donepezil; oral
N06DA02 [21604795]
4.7e+00
4.5e+00
4.0e+00
—
3.8e+00
4.3e+00
3.6e+00
cases:26.60%
controls:0.33%
cases:28.54%
controls:0.45%
cases:6.99%
controls:0.14%
—
—
cases:5.01%
controls:0.12%
cases:27.93%
controls:0.53%
cases:31.20%
controls:1.20%
137
17
378
5127
147
23
368
5121
36
7
479
5137
—
25
6
474
5124
119
26
307
4889
83
47
183
3870
rivastigmine; oral, transdermal
N06DA03 [21604796]
4.6e+00
4.7e+00
4.5e+00
—
—
4.6e+00
3.1e+00
cases:15.73%
controls:0.19%
cases:19.61%
controls:0.21%
cases:8.16%
controls:0.10%
—
—
—
—
cases:17.84%
controls:0.22%
cases:18.80%
controls:1.00%
81
10
434
5134
101
11
414
5133
42
5
473
5139
—
—
76
11
350
4904
50
39
216
3878
memantine; oral
N06DX01 [21604799]
5.2e+00
5.2e+00
—
—
—
5.2e+00
4.6e+00
cases:19.42%
controls:0.14%
cases:28.93%
controls:0.21%
—
—
—
—
—
—
cases:32.86%
controls:0.26%
cases:51.50%
controls:1.10%
100
7
415
5137
149
11
366
5133
—
—
—
140
13
286
4902
137
43
129
3874
risperidone; oral, parenteral
N05AX08 [21604559]
2.8e+00
2.9e+00
3.1e+00
—
2.8e+00
2.8e+00
2.7e+00
cases:13.40%
controls:0.97%
cases:13.98%
controls:0.87%
cases:6.60%
controls:0.31%
—
—
cases:5.61%
controls:0.37%
cases:14.79%
controls:1.08%
cases:27.44%
controls:2.40%
69
50
446
5094
72
45
443
5099
34
16
481
5128
—
28
19
471
5111
63
53
363
4862
73
94
193
3823
General Practice
1 [38004446]
1.1e+00
1.4e+00
2.2e+00
6.6e+00
2.4e+00
1.5e+00
1.1e+00
cases:51.07%
controls:25.95%
cases:41.55%
controls:15.09%
cases:19.03%
controls:2.62%
cases:53.20%
controls:0.16%
cases:25.05%
controls:2.83%
cases:49.30%
controls:17.27%
cases:70.68%
controls:43.43%
263
1335
252
3809
214
776
301
4368
98
135
417
5009
274
8
241
5136
125
145
374
4985
210
849
216
4066
188
1701
78
2216
Inpatient Hospital
21 [8717]
8.2e-01
1.0e+00
2.3e+00
7.1e+00
2.0e+00
1.1e+00
7.8e-01
cases:73.79%
controls:55.46%
cases:52.04%
controls:28.03%
cases:34.37%
controls:4.88%
cases:79.42%
controls:0.31%
cases:30.46%
controls:5.48%
cases:56.10%
controls:29.09%
cases:77.44%
controls:61.19%
380
2853
135
2291
268
1442
247
3702
177
251
338
4893
409
16
106
5128
152
281
347
4849
239
1430
187
3485
206
2397
60
1520
Alzheimer disease with late onset
G30.1 [45552521]
5.5e+00
—
—
1.0e+50
—
5.0e+00
4.3e+00
cases:19.81%
controls:0.10%
—
—
—
—
cases:1.36%
controls:0.00%
—
—
cases:13.62%
controls:0.10%
cases:25.94%
controls:0.46%
102
5
413
5139
—
—
7
0
508
5144
—
58
5
368
4910
69
18
197
3899
galantamine; oral
N06DA04 [21604797]
3.8e+00
3.8e+00
—
—
—
3.8e+00
3.3e+00
cases:7.57%
controls:0.17%
cases:7.57%
controls:0.17%
—
—
—
—
—
—
cases:7.04%
controls:0.16%
cases:7.52%
controls:0.31%
39
9
476
5135
39
9
476
5135
—
—
—
30
8
396
4907
20
12
246
3905
quetiapine; oral
N05AH04 [21604544]
2.3e+00
2.4e+00
2.6e+00
—
2.6e+00
2.4e+00
2.1e+00
cases:9.32%
controls:1.05%
cases:9.71%
controls:0.99%
cases:4.27%
controls:0.33%
—
—
cases:2.81%
controls:0.21%
cases:10.80%
controls:1.10%
cases:20.30%
controls:3.14%
48
54
467
5090
50
51
465
5093
22
17
493
5127
—
14
11
485
5119
46
54
380
4861
54
123
212
3794
Memory disturbance
P20 [2002000816]
2.2e+00
2.2e+00
2.6e+00
—
2.8e+00
2.1e+00
9.4e-01
cases:7.18%
controls:0.84%
cases:7.96%
controls:0.93%
cases:2.52%
controls:0.19%
—
—
cases:3.01%
controls:0.19%
cases:8.69%
controls:1.14%
cases:12.78%
controls:5.41%
37
43
478
5101
41
48
474
5096
13
10
502
5134
—
15
10
484
5120
37
56
389
4859
34
212
232
3705
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
307 [2001600266]
5.0e+00
4.5e+00
—
—
1.0e+50
3.2e+00
9.8e-01
cases:40.00%
controls:0.47%
cases:16.70%
controls:0.21%
—
—
—
—
cases:2.20%
controls:0.00%
cases:3.29%
controls:0.14%
cases:1.88%
controls:0.71%
206
24
309
5120
86
11
429
5133
—
—
11
0
488
5130
14
7
412
4908
5
28
261
3889
Holiday relief care
Z75.5 [45547342]
2.2e+00
2.6e+00
—
1.0e+50
—
3.2e+00
2.4e+00
cases:2.91%
controls:0.33%
cases:3.30%
controls:0.25%
—
—
cases:1.55%
controls:0.00%
—
—
cases:3.52%
controls:0.14%
cases:3.76%
controls:0.36%
15
17
500
5127
17
13
498
5131
—
8
0
507
5144
—
15
7
411
4908
10
14
256
3903
Emergency Room Visit
ER [9203]
3.8e-01
5.8e-01
2.4e+00
4.9e+00
1.4e+00
7.4e-01
1.4e-01
cases:54.17%
controls:44.63%
cases:32.04%
controls:20.96%
cases:26.80%
controls:3.19%
cases:21.55%
controls:0.19%
cases:11.82%
controls:3.33%
cases:38.26%
controls:22.91%
cases:60.90%
controls:57.47%
279
2296
236
2848
165
1078
350
4066
138
164
377
4980
111
10
404
5134
59
171
440
4959
163
1126
263
3789
162
2251
104
1666
Home Visit
OMOP4822459 [581476]
9.6e-01
1.3e+00
1.8e+00
1.7e+00
1.7e+00
1.3e+00
6.4e-01
cases:8.54%
controls:3.46%
cases:13.79%
controls:4.35%
cases:10.68%
controls:1.87%
cases:3.69%
controls:0.68%
cases:9.82%
controls:1.91%
cases:18.08%
controls:5.70%
cases:33.83%
controls:21.29%
44
178
471
4966
71
224
444
4920
55
96
460
5048
19
35
496
5109
49
98
450
5032
77
280
349
4635
90
834
176
3083
Taking care of patient’s/customer’s hygiene
SPAT1137 [2001700238]
1.3e+00
1.9e+00
2.1e+00
—
2.0e+00
2.0e+00
1.2e+00
cases:1.94%
controls:0.52%
cases:4.47%
controls:0.68%
cases:3.11%
controls:0.41%
—
—
cases:3.21%
controls:0.43%
cases:7.51%
controls:1.06%
cases:12.41%
controls:4.08%
10
27
505
5117
23
35
492
5109
16
21
499
5123
—
16
22
483
5108
32
52
394
4863
33
160
233
3757
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.6e+00
1.7e+00
2.0e+00
—
—
1.7e+00
2.0e+00
cases:2.14%
controls:0.43%
cases:2.91%
controls:0.56%
cases:1.55%
controls:0.21%
—
—
—
—
cases:2.82%
controls:0.53%
cases:6.02%
controls:0.84%
11
22
504
5122
15
29
500
5115
8
11
507
5133
—
—
12
26
414
4889
16
33
250
3884
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
1.4e+00
1.5e+00
1.7e+00
—
1.9e+00
1.6e+00
7.0e-01
cases:3.88%
controls:1.01%
cases:4.66%
controls:1.07%
cases:2.33%
controls:0.43%
—
—
cases:3.01%
controls:0.45%
cases:7.04%
controls:1.49%
cases:13.16%
controls:6.97%
20
52
495
5092
24
55
491
5089
12
22
503
5122
—
15
23
484
5107
30
73
396
4842
35
273
231
3644
Normal-pressure hydrocephalus
G91.2 [45547765]
1.8e+00
2.0e+00
—
—
—
2.5e+00
2.4e+00
cases:2.14%
controls:0.37%
cases:1.17%
controls:0.16%
—
—
—
—
—
—
cases:1.17%
controls:0.10%
cases:2.26%
controls:0.20%
11
19
504
5125
6
8
509
5136
—
—
—
5
5
421
4910
6
8
260
3909
Limited function/disability NOS
A28 [2002000162]
8.5e-01
1.1e+00
1.5e+00
2.0e+00
1.8e+00
1.3e+00
4.4e-01
cases:3.88%
controls:1.69%
cases:5.83%
controls:2.04%
cases:4.27%
controls:1.03%
cases:1.55%
controls:0.21%
cases:5.41%
controls:0.96%
cases:9.62%
controls:2.89%
cases:16.17%
controls:11.03%
20
87
495
5057
30
105
485
5039
22
53
493
5091
8
11
507
5133
27
49
472
5081
41
142
385
4773
43
432
223
3485
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
1.1e+00
1.8e+00
1.9e+00
-1.0e+50
2.1e+00
1.7e+00
9.4e-01
cases:1.55%
controls:0.54%
cases:2.52%
controls:0.45%
cases:1.36%
controls:0.21%
cases:0.00%
controls:0.12%
cases:1.80%
controls:0.21%
cases:4.46%
controls:0.81%
cases:8.65%
controls:3.57%
8
28
507
5116
13
23
502
5121
7
11
508
5133
0
6
515
5138
9
11
490
5119
19
40
407
4875
23
140
243
3777
Internal Medicine
11 [38004456]
2.9e-01
3.2e-01
1.9e+00
5.1e+00
8.4e-01
4.3e-01
5.4e-02
cases:48.35%
controls:41.15%
cases:24.66%
controls:19.17%
cases:18.64%
controls:3.36%
cases:20.78%
controls:0.16%
cases:7.62%
controls:3.45%
cases:27.00%
controls:19.39%
cases:45.11%
controls:43.78%
249
2117
266
3027
127
986
388
4158
96
173
419
4971
107
8
408
5136
38
177
461
4953
115
953
311
3962
120
1715
146
2202
Administration of medicine
SPAT1254 [2001700355]
9.5e-01
1.7e+00
2.1e+00
1.6e+00
1.9e+00
1.6e+00
7.5e-01
cases:2.72%
controls:1.07%
cases:6.02%
controls:1.11%
cases:4.66%
controls:0.60%
cases:1.55%
controls:0.33%
cases:4.81%
controls:0.74%
cases:8.92%
controls:1.87%
cases:13.53%
controls:6.87%
14
55
501
5089
31
57
484
5087
24
31
491
5113
8
17
507
5127
24
38
475
5092
38
92
388
4823
36
269
230
3648
Alzheimer disease
G30 [45538101]
5.1e+00
—
1.0e+50
—
1.0e+50
—
3.0e+00
cases:33.40%
controls:0.31%
—
—
cases:2.52%
controls:0.00%
—
—
cases:2.00%
controls:0.00%
—
—
cases:7.14%
controls:0.38%
172
16
343
5128
—
13
0
502
5144
—
10
0
489
5130
—
19
15
247
3902
Dementia
P70 [2002000864]
2.7e+00
—
—
—
—
2.8e+00
2.4e+00
cases:1.94%
controls:0.14%
—
—
—
—
—
—
—
—
cases:3.76%
controls:0.24%
cases:10.15%
controls:1.05%
10
7
505
5137
—
—
—
—
16
12
410
4903
27
41
239
3876
Unspecified dementia
F03 [45566772]
2.4e+00
2.5e+00
—
—
—
1.6e+00
9.5e-01
cases:12.43%
controls:1.22%
cases:6.99%
controls:0.62%
—
—
—
—
—
—
cases:3.52%
controls:0.75%
cases:6.77%
controls:2.73%
64
63
451
5081
36
32
479
5112
—
—
—
15
37
411
4878
18
107
248
3810
Urinary tract infection, site not specified
N39.0 [45548665]
2.7e-01
1.2e+00
2.7e+00
—
2.3e+00
1.1e+00
6.1e-01
cases:3.88%
controls:2.99%
cases:3.69%
controls:1.11%
cases:3.30%
controls:0.23%
—
—
cases:1.00%
controls:0.10%
cases:4.46%
controls:1.51%
cases:10.53%
controls:6.00%
20
154
495
4990
19
57
496
5087
17
12
498
5132
—
5
5
494
5125
19
74
407
4841
28
235
238
3682
mirtazapine; oral
N06AX11 [21604740]
1.3e+00
1.3e+00
1.7e+00
—
1.2e+00
1.1e+00
7.1e-01
cases:14.37%
controls:4.37%
cases:11.46%
controls:3.36%
cases:4.85%
controls:0.95%
—
—
cases:3.21%
controls:0.97%
cases:10.33%
controls:3.70%
cases:18.05%
controls:9.78%
74
225
441
4919
59
173
456
4971
25
49
490
5095
—
16
50
483
5080
44
182
382
4733
48
383
218
3534
haloperidol; oral, parenteral
N05AD01 [21604516]
2.6e+00
2.5e+00
—
—
—
2.1e+00
1.5e+00
cases:4.08%
controls:0.31%
cases:2.14%
controls:0.17%
—
—
—
—
—
—
cases:1.88%
controls:0.22%
cases:2.26%
controls:0.51%
21
16
494
5128
11
9
504
5135
—
—
—
8
11
418
4904
6
20
260
3897
Provision of support and information to patient’s family members
SPAT1245 [2001700346]
2.9e+00
2.0e+00
—
—
—
2.2e+00
8.1e-01
cases:2.33%
controls:0.14%
cases:1.55%
controls:0.21%
—
—
—
—
—
—
cases:2.58%
controls:0.28%
cases:4.51%
controls:2.07%
12
7
503
5137
8
11
507
5133
—
—
—
11
14
415
4901
12
81
254
3836
Neurology
13 [38004458]
1.3e+00
1.3e+00
2.0e+00
—
1.3e+00
9.6e-01
-1.3e-01
cases:35.92%
controls:13.57%
cases:18.83%
controls:5.70%
cases:5.83%
controls:0.86%
—
—
cases:3.41%
controls:0.94%
cases:13.85%
controls:5.82%
cases:15.41%
controls:17.13%
185
698
330
4446
97
293
418
4851
30
44
485
5100
—
17
48
482
5082
59
286
367
4629
41
671
225
3246
Malaise and fatigue
R53 [45553741]
1.1e+00
1.6e+00
2.9e+00
—
1.8e+00
1.1e+00
3.6e-01
cases:8.74%
controls:2.95%
cases:6.41%
controls:1.38%
cases:4.85%
controls:0.27%
—
—
cases:1.20%
controls:0.19%
cases:5.87%
controls:2.01%
cases:11.65%
controls:8.40%
45
152
470
4992
33
71
482
5073
25
14
490
5130
—
6
10
493
5120
25
99
401
4816
31
329
235
3588
No procedures
SPAT1301 [2001700402]
6.2e-01
7.4e-01
1.6e+00
2.1e+00
1.6e+00
7.7e-01
-1.4e-01
cases:4.85%
controls:2.66%
cases:5.83%
controls:2.86%
cases:3.69%
controls:0.78%
cases:1.55%
controls:0.19%
cases:3.81%
controls:0.82%
cases:7.04%
controls:3.40%
cases:11.65%
controls:13.22%
25
137
490
5007
30
147
485
4997
19
40
496
5104
8
10
507
5134
19
42
480
5088
30
167
396
4748
31
518
235
3399
Geriatric Medicine
38 [38004478]
2.0e+00
2.5e+00
—
1.0e+50
—
2.1e+00
5.1e-01
cases:6.60%
controls:0.91%
cases:4.27%
controls:0.37%
—
—
cases:2.14%
controls:0.00%
—
—
cases:3.05%
controls:0.37%
cases:3.76%
controls:2.30%
34
47
481
5097
22
19
493
5125
—
11
0
504
5144
—
13
18
413
4897
10
90
256
3827
CBC panel - Blood by Automated count
58410-2 [40761511]
8.0e-02
4.3e-01
1.1e+00
3.5e+00
1.9e+00
1.5e-01
7.8e-02
cases:5.24%
controls:4.86%
cases:7.18%
controls:4.78%
cases:4.08%
controls:1.34%
cases:3.11%
controls:0.10%
cases:5.61%
controls:0.90%
cases:8.45%
controls:7.37%
cases:33.08%
controls:31.38%
27
250
488
4894
37
246
478
4898
21
69
494
5075
16
5
499
5139
28
46
471
5084
36
362
390
4553
88
1229
178
2688
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
8.9e-01
3.8e-01
2.1e+00
—
1.8e+00
1.1e+00
6.4e-01
cases:14.95%
controls:6.73%
cases:4.47%
controls:3.09%
cases:3.11%
controls:0.41%
—
—
cases:2.00%
controls:0.33%
cases:9.86%
controls:3.50%
cases:21.43%
controls:12.54%
77
346
438
4798
23
159
492
4985
16
21
499
5123
—
10
17
489
5113
42
172
384
4743
57
491
209
3426
oxazepam; oral
N05BA04 [21604569]
9.2e-01
1.1e+00
1.0e+00
—
1.6e+00
1.5e+00
1.4e+00
cases:12.62%
controls:5.46%
cases:10.10%
controls:3.69%
cases:2.52%
controls:0.93%
—
—
cases:4.01%
controls:0.84%
cases:13.85%
controls:3.48%
cases:22.18%
controls:6.69%
65
281
450
4863
52
190
463
4954
13
48
502
5096
—
20
43
479
5087
59
171
367
4744
59
262
207
3655
Geriatric Psychiatry
27 [38004470]
2.2e+00
1.8e+00
—
1.0e+50
—
2.3e+00
9.8e-01
cases:3.69%
controls:0.41%
cases:1.36%
controls:0.23%
—
—
cases:2.52%
controls:0.00%
—
—
cases:2.35%
controls:0.24%
cases:1.88%
controls:0.71%
19
21
496
5123
7
12
508
5132
—
13
0
502
5144
—
10
12
416
4903
5
28
261
3889
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-8.0e-02
2.1e-01
1.1e+00
3.4e+00
1.7e+00
1.7e-01
2.5e-02
cases:5.24%
controls:5.66%
cases:7.57%
controls:6.24%
cases:4.66%
controls:1.67%
cases:3.30%
controls:0.12%
cases:6.41%
controls:1.25%
cases:10.33%
controls:8.83%
cases:37.59%
controls:37.02%
27
291
488
4853
39
321
476
4823
24
86
491
5058
17
6
498
5138
32
64
467
5066
44
434
382
4481
100
1450
166
2467
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-4.2e-02
2.2e-01
1.1e+00
3.4e+00
1.7e+00
1.6e-01
1.7e-02
cases:5.44%
controls:5.66%
cases:7.77%
controls:6.36%
cases:4.66%
controls:1.67%
cases:3.30%
controls:0.12%
cases:6.41%
controls:1.29%
cases:10.33%
controls:8.93%
cases:37.59%
controls:37.20%
28
291
487
4853
40
327
475
4817
24
86
491
5058
17
6
498
5138
32
66
467
5064
44
439
382
4476
100
1457
166
2460
Weakness/tiredness general
A04 [2002000145]
5.6e-01
1.3e+00
2.3e+00
—
—
1.3e+00
1.0e+00
cases:1.55%
controls:0.89%
cases:2.52%
controls:0.72%
cases:1.17%
controls:0.12%
—
—
—
—
cases:3.52%
controls:1.00%
cases:11.28%
controls:4.29%
8
46
507
5098
13
37
502
5107
6
6
509
5138
—
—
15
49
411
4866
30
168
236
3749
Nursing episode
950 [44777714]
8.5e-01
1.0e+00
1.1e+00
—
1.2e+00
1.2e+00
6.4e-01
cases:4.27%
controls:1.87%
cases:5.83%
controls:2.18%
cases:2.72%
controls:0.95%
—
—
cases:3.21%
controls:1.01%
cases:8.22%
controls:2.73%
cases:19.17%
controls:11.16%
22
96
493
5048
30
112
485
5032
14
49
501
5095
—
16
52
483
5078
35
134
391
4781
51
437
215
3480
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-7.8e-02
1.8e-01
8.8e-01
3.4e+00
1.4e+00
1.9e-01
2.3e-02
cases:5.44%
controls:5.85%
cases:7.77%
controls:6.59%
cases:4.47%
controls:1.91%
cases:3.50%
controls:0.12%
cases:6.21%
controls:1.56%
cases:11.27%
controls:9.46%
cases:38.35%
controls:37.81%
28
301
487
4843
40
339
475
4805
23
98
492
5046
18
6
497
5138
31
80
468
5050
48
465
378
4450
102
1481
164
2436
Functional capacity evaluation
443351003 [40481051]
1.0e+00
1.6e+00
—
—
2.3e+00
1.6e+00
6.7e-01
cases:2.72%
controls:0.99%
cases:3.88%
controls:0.82%
—
—
—
—
cases:2.20%
controls:0.23%
cases:4.69%
controls:1.02%
cases:11.65%
controls:6.33%
14
51
501
5093
20
42
495
5102
—
—
11
12
488
5118
20
50
406
4865
31
248
235
3669
Psychiatry
26 [38004469]
1.6e+00
1.6e+00
2.3e+00
1.0e+50
2.2e+00
1.3e+00
1.4e-01
cases:6.41%
controls:1.38%
cases:2.33%
controls:0.47%
cases:0.97%
controls:0.10%
cases:2.72%
controls:0.00%
cases:1.20%
controls:0.14%
cases:2.11%
controls:0.61%
cases:1.88%
controls:1.63%
33
71
482
5073
12
24
503
5120
5
5
510
5139
14
0
501
5144
6
7
493
5123
9
30
417
4885
5
64
261
3853
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-6.9e-02
1.9e-01
7.3e-01
3.4e+00
1.6e+00
1.8e-01
5.4e-03
cases:5.63%
controls:6.01%
cases:7.96%
controls:6.65%
cases:4.27%
controls:2.10%
cases:3.50%
controls:0.12%
cases:7.01%
controls:1.52%
cases:11.50%
controls:9.83%
cases:38.35%
controls:38.22%
29
309
486
4835
41
342
474
4802
22
108
493
5036
18
6
497
5138
35
78
464
5052
49
483
377
4432
102
1497
164
2420
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
F00.10*G30.1 [2000501573]
1.0e+50
—
1.0e+50
—
1.0e+50
—
5.0e+00
cases:8.74%
controls:0.00%
—
—
cases:1.55%
controls:0.00%
—
—
cases:2.00%
controls:0.00%
—
—
cases:16.17%
controls:0.13%
45
0
470
5144
—
8
0
507
5144
—
10
0
489
5130
—
43
5
223
3912
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-7.2e-02
1.9e-01
7.4e-01
3.5e+00
1.5e+00
1.1e-01
-6.0e-02
cases:5.63%
controls:6.03%
cases:7.96%
controls:6.65%
cases:4.27%
controls:2.08%
cases:3.69%
controls:0.12%
cases:6.81%
controls:1.58%
cases:10.80%
controls:9.77%
cases:36.84%
controls:38.24%
29
310
486
4834
41
342
474
4802
22
107
493
5037
19
6
496
5138
34
81
465
5049
46
480
380
4435
98
1498
168
2419
Platelets [#/volume] in Blood
26515-7 [3007461]
-6.2e-02
2.0e-01
7.5e-01
3.4e+00
1.6e+00
1.2e-01
-5.3e-02
cases:5.63%
controls:5.97%
cases:7.96%
controls:6.61%
cases:4.27%
controls:2.06%
cases:3.50%
controls:0.12%
cases:6.81%
controls:1.52%
cases:10.80%
controls:9.73%
cases:36.84%
controls:38.09%
29
307
486
4837
41
340
474
4804
22
106
493
5038
18
6
497
5138
34
78
465
5052
46
478
380
4437
98
1492
168
2425
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-6.5e-02
2.0e-01
7.4e-01
3.4e+00
1.6e+00
1.2e-01
-5.4e-02
cases:5.63%
controls:5.99%
cases:7.96%
controls:6.63%
cases:4.27%
controls:2.08%
cases:3.50%
controls:0.12%
cases:6.81%
controls:1.52%
cases:10.80%
controls:9.73%
cases:36.84%
controls:38.12%
29
308
486
4836
41
341
474
4803
22
107
493
5037
18
6
497
5138
34
78
465
5052
46
478
380
4437
98
1493
168
2424
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-6.5e-02
2.0e-01
7.4e-01
3.4e+00
1.6e+00
1.1e-01
-5.4e-02
cases:5.63%
controls:5.99%
cases:7.96%
controls:6.63%
cases:4.27%
controls:2.08%
cases:3.50%
controls:0.12%
cases:6.81%
controls:1.52%
cases:10.80%
controls:9.75%
cases:36.84%
controls:38.12%
29
308
486
4836
41
341
474
4803
22
107
493
5037
18
6
497
5138
34
78
465
5052
46
479
380
4436
98
1493
168
2424
MCH [Entitic mass]
28539-5 [3035941]
-6.5e-02
2.0e-01
7.4e-01
3.4e+00
1.6e+00
1.2e-01
-5.4e-02
cases:5.63%
controls:5.99%
cases:7.96%
controls:6.63%
cases:4.27%
controls:2.08%
cases:3.50%
controls:0.12%
cases:6.81%
controls:1.52%
cases:10.80%
controls:9.73%
cases:36.84%
controls:38.12%
29
308
486
4836
41
341
474
4803
22
107
493
5037
18
6
497
5138
34
78
465
5052
46
478
380
4437
98
1493
168
2424
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-6.5e-02
1.9e-01
7.4e-01
3.4e+00
1.6e+00
1.1e-01
-5.5e-02
cases:5.63%
controls:5.99%
cases:7.96%
controls:6.65%
cases:4.27%
controls:2.08%
cases:3.50%
controls:0.12%
cases:6.81%
controls:1.52%
cases:10.80%
controls:9.75%
cases:36.84%
controls:38.14%
29
308
486
4836
41
342
474
4802
22
107
493
5037
18
6
497
5138
34
78
465
5052
46
479
380
4436
98
1494
168
2423
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-1.3e-01
2.2e-01
9.5e-01
3.4e+00
1.4e+00
3.0e-01
3.2e-02
cases:2.91%
controls:3.30%
cases:4.27%
controls:3.46%
cases:3.11%
controls:1.22%
cases:2.91%
controls:0.10%
cases:3.61%
controls:0.90%
cases:6.81%
controls:5.15%
cases:21.05%
controls:20.53%
15
170
500
4974
22
178
493
4966
16
63
499
5081
15
5
500
5139
18
46
481
5084
29
253
397
4662
56
804
210
3113
citalopram; oral, parenteral
N06AB04 [21604712]
1.3e+00
1.3e+00
8.5e-01
—
8.2e-01
1.1e+00
1.1e+00
cases:16.50%
controls:5.29%
cases:11.65%
controls:3.34%
cases:2.33%
controls:1.01%
—
—
cases:1.80%
controls:0.80%
cases:9.86%
controls:3.44%
cases:12.78%
controls:4.60%
85
272
430
4872
60
172
455
4972
12
52
503
5092
—
9
41
490
5089
42
169
384
4746
34
180
232
3737
Other amnesia
R41.3 [45539342]
2.3e+00
2.5e+00
—
—
—
-1.0e+50
-1.0e+50
cases:2.14%
controls:0.21%
cases:1.17%
controls:0.10%
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:0.00%
controls:0.74%
11
11
504
5133
6
5
509
5139
—
—
—
0
15
426
4900
0
29
266
3888
General Surgery
2 [38004447]
-2.3e-02
-1.2e-01
1.2e+00
3.6e+00
6.5e-01
2.0e-01
-2.6e-01
cases:33.59%
controls:34.10%
cases:10.68%
controls:11.88%
cases:6.41%
controls:2.06%
cases:3.30%
controls:0.10%
cases:3.41%
controls:1.81%
cases:14.08%
controls:11.86%
cases:21.43%
controls:26.07%
173
1754
342
3390
55
611
460
4533
33
106
482
5038
17
5
498
5139
17
93
482
5037
60
583
366
4332
57
1021
209
2896
Urgent procedure
ZXD05 [2001311386]
6.0e-02
-5.1e-02
2.3e+00
—
2.3e+00
5.9e-01
-1.6e-01
cases:6.99%
controls:6.61%
cases:2.33%
controls:2.45%
cases:1.75%
controls:0.17%
—
—
cases:1.20%
controls:0.12%
cases:3.99%
controls:2.26%
cases:7.14%
controls:8.30%
36
340
479
4804
12
126
503
5018
9
9
506
5135
—
6
6
493
5124
17
111
409
4804
19
325
247
3592
Medication/prescr/renewal
-50 [2002000121]
1.0e+00
2.1e+00
2.5e+00
—
—
1.3e+00
—
cases:1.36%
controls:0.51%
cases:1.94%
controls:0.23%
cases:1.17%
controls:0.10%
—
—
—
—
cases:1.64%
controls:0.45%
—
—
7
26
508
5118
10
12
505
5132
6
5
509
5139
—
—
7
22
419
4893
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
1.1e+00
1.3e+00
2.0e+00
—
—
1.2e+00
5.7e-01
cases:2.14%
controls:0.72%
cases:2.33%
controls:0.62%
cases:1.17%
controls:0.16%
—
—
—
—
cases:3.52%
controls:1.04%
cases:7.89%
controls:4.62%
11
37
504
5107
12
32
503
5112
6
8
509
5136
—
—
15
51
411
4864
21
181
245
3736
Blood test
-34 [2002000105]
—
2.6e+00
1.0e+50
—
—
1.9e+00
—
—
—
cases:1.36%
controls:0.10%
cases:0.97%
controls:0.00%
—
—
—
—
cases:1.41%
controls:0.20%
—
—
—
7
5
508
5139
5
0
510
5144
—
—
6
10
420
4905
—
Observation for suspected nervous system disorder
Z03.3 [45609903]
1.9e+00
2.6e+00
—
—
—
—
—
cases:2.91%
controls:0.45%
cases:1.36%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
15
23
500
5121
7
5
508
5139
—
—
—
—
—
escitalopram; oral
N06AB10 [21604718]
1.2e+00
1.1e+00
8.7e-01
—
1.1e+00
1.1e+00
1.1e+00
cases:5.44%
controls:1.75%
cases:4.08%
controls:1.42%
cases:0.97%
controls:0.41%
—
—
cases:1.60%
controls:0.53%
cases:5.16%
controls:1.71%
cases:9.02%
controls:3.14%
28
90
487
5054
21
73
494
5071
5
21
510
5123
—
8
27
491
5103
22
84
404
4831
24
123
242
3794
Bacteria identified in Blood by Culture
600-7 [3023368]
—
8.6e-01
2.2e+00
—
2.3e+00
4.1e-01
5.3e-01
—
—
cases:1.55%
controls:0.66%
cases:1.17%
controls:0.14%
—
—
cases:1.00%
controls:0.10%
cases:1.41%
controls:0.94%
cases:11.28%
controls:6.97%
—
8
34
507
5110
6
7
509
5137
—
5
5
494
5125
6
46
420
4869
30
273
236
3644
Case Management Agency
251B00000X [38004193]
1.0e+00
5.0e-01
5.7e-01
2.9e+00
3.6e-01
-1.2e-01
-4.8e-01
cases:66.60%
controls:42.15%
cases:47.18%
controls:35.09%
cases:19.22%
controls:11.82%
cases:10.10%
controls:0.62%
cases:16.83%
controls:12.34%
cases:39.67%
controls:42.50%
cases:64.29%
controls:74.44%
343
2168
172
2976
243
1805
272
3339
99
608
416
4536
52
32
463
5112
84
633
415
4497
169
2089
257
2826
171
2916
95
1001
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.8e-02
7.1e-02
1.0e+00
2.8e+00
1.6e+00
7.7e-02
6.9e-02
cases:3.11%
controls:2.99%
cases:4.08%
controls:3.81%
cases:2.72%
controls:0.99%
cases:1.55%
controls:0.10%
cases:3.81%
controls:0.80%
cases:5.16%
controls:4.80%
cases:21.43%
controls:20.30%
16
154
499
4990
21
196
494
4948
14
51
501
5093
8
5
507
5139
19
41
480
5089
22
236
404
4679
57
795
209
3122
Overall medication plan or its review
SPAT1252 [2001700353]
6.6e-01
1.5e+00
1.8e+00
—
2.8e+00
1.2e+00
3.9e-01
cases:0.97%
controls:0.51%
cases:2.14%
controls:0.47%
cases:0.97%
controls:0.16%
—
—
cases:1.60%
controls:0.10%
cases:2.11%
controls:0.65%
cases:3.76%
controls:2.58%
5
26
510
5118
11
24
504
5120
5
8
510
5136
—
8
5
491
5125
9
32
417
4883
10
101
256
3816
Counselling and guidance related to ageing
SPAT1304 [2001700405]
9.2e-01
1.2e+00
—
—
2.7e+00
1.6e+00
6.0e-01
cases:1.36%
controls:0.54%
cases:1.17%
controls:0.37%
—
—
—
—
cases:1.40%
controls:0.10%
cases:2.35%
controls:0.49%
cases:6.39%
controls:3.63%
7
28
508
5116
6
19
509
5125
—
—
7
5
492
5125
10
24
416
4891
17
142
249
3775
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
2.1e+00
2.1e+00
—
—
—
1.1e+00
3.4e-01
cases:6.99%
controls:0.91%
cases:3.30%
controls:0.41%
—
—
—
—
—
—
cases:1.17%
controls:0.41%
cases:2.63%
controls:1.89%
36
47
479
5097
17
21
498
5123
—
—
—
5
20
421
4895
7
74
259
3843
olanzapine; oral, parenteral
N05AH03 [21604543]
1.6e+00
2.0e+00
—
—
—
1.8e+00
2.1e+00
cases:1.17%
controls:0.23%
cases:1.36%
controls:0.19%
—
—
—
—
—
—
cases:1.41%
controls:0.24%
cases:4.51%
controls:0.56%
6
12
509
5132
7
10
508
5134
—
—
—
6
12
420
4903
12
22
254
3895
Supine thorax X-ray examination
GD1QA [2001303648]
6.1e-01
6.2e-01
2.3e+00
—
—
8.6e-01
8.9e-01
cases:4.27%
controls:2.37%
cases:3.11%
controls:1.69%
cases:2.33%
controls:0.23%
—
—
—
—
cases:4.93%
controls:2.16%
cases:19.55%
controls:9.11%
22
122
493
5022
16
87
499
5057
12
12
503
5132
—
—
21
106
405
4809
52
357
214
3560
Support of social functional capacity
SPAT1234 [2001700335]
1.7e+00
2.1e+00
—
—
—
1.9e+00
7.3e-01
cases:0.97%
controls:0.17%
cases:1.75%
controls:0.21%
—
—
—
—
—
—
cases:2.35%
controls:0.37%
cases:4.14%
controls:2.04%
5
9
510
5135
9
11
506
5133
—
—
—
10
18
416
4897
11
80
255
3837
lactulose; oral
A06AD11 [21600571]
7.8e-01
1.0e+00
9.0e-01
—
9.0e-02
1.0e+00
1.1e+00
cases:12.04%
controls:5.89%
cases:7.77%
controls:2.88%
cases:1.94%
controls:0.80%
—
—
cases:1.00%
controls:0.92%
cases:9.62%
controls:3.78%
cases:22.93%
controls:8.81%
62
303
453
4841
40
148
475
4996
10
41
505
5103
—
5
47
494
5083
41
186
385
4729
61
345
205
3572
Sampling
SPAT1263 [2001700364]
6.8e-01
8.6e-01
1.1e+00
—
1.3e+00
6.4e-01
2.7e-01
cases:5.44%
controls:2.82%
cases:6.99%
controls:3.09%
cases:2.91%
controls:0.97%
—
—
cases:3.41%
controls:0.97%
cases:8.45%
controls:4.64%
cases:19.92%
controls:15.98%
28
145
487
4999
36
159
479
4985
15
50
500
5094
—
17
50
482
5080
36
228
390
4687
53
626
213
3291
Laboratory Visit
OMOP4822461 [32036]
-3.3e-02
9.0e-02
5.1e-01
3.1e+00
8.1e-01
1.1e-01
-3.1e-02
cases:6.41%
controls:6.61%
cases:8.74%
controls:8.05%
cases:6.21%
controls:3.81%
cases:4.85%
controls:0.23%
cases:7.82%
controls:3.65%
cases:12.68%
controls:11.52%
cases:40.23%
controls:40.98%
33
340
482
4804
45
414
470
4730
32
196
483
4948
25
12
490
5132
39
187
460
4943
54
566
372
4349
107
1605
159
2312
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
1.1e+00
1.0e+00
—
—
—
1.2e+00
1.5e+00
cases:3.69%
controls:1.26%
cases:2.52%
controls:0.93%
—
—
—
—
—
—
cases:3.29%
controls:1.02%
cases:8.65%
controls:2.04%
19
65
496
5079
13
48
502
5096
—
—
—
14
50
412
4865
23
80
243
3837
hydrocortisone; oral, parenteral
H02AB09 [21602737]
6.9e-02
5.8e-01
-1.0e+50
—
2.3e+00
1.4e+00
2.5e-01
cases:1.75%
controls:1.63%
cases:0.97%
controls:0.54%
cases:0.00%
controls:0.12%
—
—
cases:1.00%
controls:0.10%
cases:2.35%
controls:0.61%
cases:2.26%
controls:1.76%
9
84
506
5060
5
28
510
5116
0
6
515
5138
—
5
5
494
5125
10
30
416
4885
6
69
260
3848
Treatment of a patient needing special arrangements
WYA30 [2001310874]
1.4e+00
—
—
—
—
1.9e+00
1.7e+00
cases:0.97%
controls:0.23%
—
—
—
—
—
—
—
—
cases:1.88%
controls:0.28%
cases:9.40%
controls:1.84%
5
12
510
5132
—
—
—
—
8
14
418
4901
25
72
241
3845
Microorganisms panel - Urine sediment
58435-9 [40761536]
1.7e+00
1.9e+00
—
—
—
—
3.7e-01
cases:1.94%
controls:0.37%
cases:1.36%
controls:0.21%
—
—
—
—
—
—
—
—
cases:3.01%
controls:2.09%
10
19
505
5125
7
11
508
5133
—
—
—
—
8
82
258
3835
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
1.6e+00
1.8e+00
—
—
—
1.1e+00
6.6e-01
cases:2.14%
controls:0.43%
cases:2.91%
controls:0.51%
—
—
—
—
—
—
cases:1.64%
controls:0.53%
cases:7.14%
controls:3.83%
11
22
504
5122
15
26
500
5118
—
—
—
7
26
419
4889
19
150
247
3767
Acute tubulo-interstitial nephritis
N10 [45543856]
6.8e-01
9.3e-01
2.3e+00
1.0e+50
—
8.7e-01
9.6e-01
cases:4.85%
controls:2.53%
cases:2.72%
controls:1.09%
cases:2.14%
controls:0.21%
cases:1.55%
controls:0.00%
—
—
cases:3.52%
controls:1.51%
cases:13.16%
controls:5.46%
25
130
490
5014
14
56
501
5088
11
11
504
5133
8
0
507
5144
—
15
74
411
4841
35
214
231
3703
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
2.9e-01
6.4e-01
1.3e+00
—
1.3e+00
4.1e-01
-8.3e-02
cases:11.26%
controls:8.71%
cases:7.77%
controls:4.24%
cases:2.72%
controls:0.74%
—
—
cases:3.41%
controls:0.96%
cases:7.75%
controls:5.27%
cases:12.78%
controls:13.74%
58
448
457
4696
40
218
475
4926
14
38
501
5106
—
17
49
482
5081
33
259
393
4656
34
538
232
3379
Pneumonia, unspecified
J18.9 [45601123]
4.1e-01
5.8e-01
1.8e+00
—
1.1e+00
8.2e-01
6.2e-01
cases:8.93%
controls:6.08%
cases:4.27%
controls:2.45%
cases:2.52%
controls:0.43%
—
—
cases:1.80%
controls:0.58%
cases:8.45%
controls:3.91%
cases:23.68%
controls:14.27%
46
313
469
4831
22
126
493
5018
13
22
502
5122
—
9
30
490
5100
36
192
390
4723
63
559
203
3358
ferrous glycine sulfate; oral
B03AA01 [21601080]
1.7e+00
1.0e+00
—
—
—
1.5e+00
-2.4e-01
cases:1.55%
controls:0.29%
cases:0.97%
controls:0.35%
—
—
—
—
—
—
cases:2.35%
controls:0.51%
cases:3.01%
controls:3.80%
8
15
507
5129
5
18
510
5126
—
—
—
10
25
416
4890
8
149
258
3768
INR in Blood by Coagulation assay
34714-6 [3032080]
2.4e-01
3.0e-01
4.0e-01
3.1e+00
4.9e-01
1.2e-01
-3.3e-02
cases:3.11%
controls:2.47%
cases:3.50%
controls:2.62%
cases:2.14%
controls:1.44%
cases:2.52%
controls:0.12%
cases:2.40%
controls:1.48%
cases:3.99%
controls:3.56%
cases:16.54%
controls:17.00%
16
127
499
5017
18
135
497
5009
11
74
504
5070
13
6
502
5138
12
76
487
5054
17
175
409
4740
44
666
222
3251
Memory test
SPAT1053 [2001700154]
1.5e+00
1.6e+00
—
—
—
9.5e-01
5.4e-01
cases:4.47%
controls:1.03%
cases:4.08%
controls:0.86%
—
—
—
—
—
—
cases:3.29%
controls:1.30%
cases:10.15%
controls:6.18%
23
53
492
5091
21
44
494
5100
—
—
—
14
64
412
4851
27
242
239
3675
Organisation of medication
SPAT1251 [2001700352]
1.4e+00
1.5e+00
1.9e+00
—
—
2.7e-01
4.4e-01
cases:3.11%
controls:0.76%
cases:3.30%
controls:0.72%
cases:1.17%
controls:0.17%
—
—
—
—
cases:1.17%
controls:0.90%
cases:3.76%
controls:2.45%
16
39
499
5105
17
37
498
5107
6
9
509
5135
—
—
5
44
421
4871
10
96
256
3821
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
8.1e-01
7.6e-01
2.0e+00
—
2.1e+00
8.8e-01
3.1e-01
cases:2.33%
controls:1.05%
cases:2.33%
controls:1.11%
cases:0.97%
controls:0.14%
—
—
cases:1.20%
controls:0.16%
cases:4.46%
controls:1.89%
cases:10.53%
controls:7.94%
12
54
503
5090
12
57
503
5087
5
7
510
5137
—
6
8
493
5122
19
93
407
4822
28
311
238
3606
Mild cognitive disorder
F06.7 [45605450]
2.9e+00
2.1e+00
—
—
—
—
—
cases:2.14%
controls:0.12%
cases:0.97%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
11
6
504
5138
5
6
510
5138
—
—
—
—
—
Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]
—
1.1e+00
1.7e+00
—
1.4e+00
1.2e+00
7.0e-01
—
—
cases:1.55%
controls:0.54%
cases:1.55%
controls:0.29%
—
—
cases:1.20%
controls:0.29%
cases:3.05%
controls:0.92%
cases:6.39%
controls:3.29%
—
8
28
507
5116
8
15
507
5129
—
6
15
493
5115
13
45
413
4870
17
129
249
3788
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
1.1e+00
1.5e+00
1.6e+00
—
2.0e+00
1.3e+00
3.1e-01
cases:1.75%
controls:0.58%
cases:2.14%
controls:0.47%
cases:0.97%
controls:0.19%
—
—
cases:1.00%
controls:0.14%
cases:3.05%
controls:0.83%
cases:5.26%
controls:3.91%
9
30
506
5114
11
24
504
5120
5
10
510
5134
—
5
7
494
5123
13
41
413
4874
14
153
252
3764
macrogol; oral
A06AD15 [21600575]
1.0e+00
7.8e-01
—
—
—
1.7e+00
1.1e+00
cases:1.17%
controls:0.43%
cases:0.97%
controls:0.45%
—
—
—
—
—
—
cases:3.52%
controls:0.69%
cases:10.53%
controls:3.60%
6
22
509
5122
5
23
510
5121
—
—
—
15
34
411
4881
28
141
238
3776
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
2.8e-01
5.5e-01
1.7e+00
1.0e+50
2.7e+00
2.8e-01
1.1e-01
cases:1.94%
controls:1.48%
cases:2.14%
controls:1.24%
cases:0.97%
controls:0.17%
cases:1.94%
controls:0.00%
cases:1.40%
controls:0.10%
cases:2.11%
controls:1.61%
cases:13.91%
controls:12.66%
10
76
505
5068
11
64
504
5080
5
9
510
5135
10
0
505
5144
7
5
492
5125
9
79
417
4836
37
496
229
3421
General symptom/complaint other
A29 [2002000163]
6.7e-01
1.4e+00
—
—
—
1.3e+00
1.1e-01
cases:1.36%
controls:0.70%
cases:2.33%
controls:0.60%
—
—
—
—
—
—
cases:3.29%
controls:0.94%
cases:3.76%
controls:3.37%
7
36
508
5108
12
31
503
5113
—
—
—
14
46
412
4869
10
132
256
3785
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
2.4e+00
—
—
—
—
—
-1.0e+50
cases:1.75%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
9
8
506
5136
—
—
—
—
—
0
15
266
3902
Home visit
WYA20 [2001310873]
—
—
—
—
—
-1.0e+50
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:6.02%
controls:0.59%
—
—
—
—
—
0
8
426
4907
16
23
250
3894
Outpatient Hospital
22 [8756]
2.2e-03
2.4e-01
1.4e+00
—
9.1e-01
2.9e-01
-2.2e-01
cases:38.45%
controls:38.39%
cases:19.03%
controls:15.59%
cases:8.93%
controls:2.26%
—
—
cases:6.21%
controls:2.59%
cases:20.19%
controls:15.91%
cases:38.35%
controls:43.55%
198
1975
317
3169
98
802
417
4342
46
116
469
5028
—
31
133
468
4997
86
782
340
4133
102
1706
164
2211
Pure hypercholesterolaemia
E78.01 [2000501514]
3.2e-01
—
—
1.0e+50
2.3e+00
—
-5.0e-01
cases:3.30%
controls:2.41%
—
—
—
—
cases:1.17%
controls:0.00%
cases:1.20%
controls:0.12%
—
—
cases:3.38%
controls:5.46%
17
124
498
5020
—
—
6
0
509
5144
6
6
493
5124
—
9
214
257
3703
Chronic kidney disease, unspecified
N18.9 [45553438]
5.5e-01
3.6e-01
2.3e+00
—
—
1.3e-01
—
cases:1.75%
controls:1.01%
cases:1.36%
controls:0.95%
cases:1.36%
controls:0.14%
—
—
—
—
cases:1.41%
controls:1.24%
—
—
9
52
506
5092
7
49
508
5095
7
7
508
5137
—
—
6
61
420
4854
—
Office Visit
OMOP4822458 [581477]
3.4e-01
6.6e-01
1.6e+00
—
8.7e-01
2.1e-01
-4.1e-01
cases:15.92%
controls:11.86%
cases:7.96%
controls:4.30%
cases:2.52%
controls:0.51%
—
—
cases:1.80%
controls:0.76%
cases:5.87%
controls:4.82%
cases:11.28%
controls:16.08%
82
610
433
4534
41
221
474
4923
13
26
502
5118
—
9
39
490
5091
25
237
401
4678
30
630
236
3287
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
1.2e+00
1.1e+00
—
—
—
2.3e+00
5.5e-01
cases:1.17%
controls:0.35%
cases:0.97%
controls:0.31%
—
—
—
—
—
—
cases:2.35%
controls:0.24%
cases:4.51%
controls:2.66%
6
18
509
5126
5
16
510
5128
—
—
—
10
12
416
4903
12
104
254
3813
Atrial fibrillation and flutter
I48 [45596206]
1.1e-01
1.4e-01
1.3e+00
—
9.8e-01
9.8e-02
-5.3e-01
cases:14.37%
controls:13.06%
cases:8.93%
controls:7.85%
cases:4.66%
controls:1.34%
—
—
cases:4.61%
controls:1.77%
cases:10.09%
controls:9.24%
cases:15.41%
controls:23.69%
74
672
441
4472
46
404
469
4740
24
69
491
5075
—
23
91
476
5039
43
454
383
4461
41
928
225
2989
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.26%
controls:0.26%
—
—
—
—
—
—
6
10
260
3907
Chest pain, unspecified
R07.4 [45558450]
4.2e-01
6.3e-01
1.9e+00
—
2.2e+00
5.8e-01
-6.4e-01
cases:6.99%
controls:4.70%
cases:2.14%
controls:1.15%
cases:1.17%
controls:0.17%
—
—
cases:1.20%
controls:0.14%
cases:3.29%
controls:1.87%
cases:3.76%
controls:6.92%
36
242
479
4902
11
59
504
5085
6
9
509
5135
—
6
7
493
5123
14
92
412
4823
10
271
256
3646
12 lead EKG panel
34534-8 [3044889]
3.5e-01
1.7e-01
—
—
2.2e+00
2.0e-01
-3.5e-01
cases:3.88%
controls:2.78%
cases:2.91%
controls:2.47%
—
—
—
—
cases:1.20%
controls:0.14%
cases:3.76%
controls:3.09%
cases:13.53%
controls:18.23%
20
143
495
5001
15
127
500
5017
—
—
6
7
493
5123
16
152
410
4763
36
714
230
3203
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
4.8e-01
3.1e-01
1.4e+00
—
2.2e+00
7.0e-01
-2.9e-02
cases:2.33%
controls:1.46%
cases:1.75%
controls:1.28%
cases:0.97%
controls:0.23%
—
—
cases:1.20%
controls:0.14%
cases:3.05%
controls:1.55%
cases:10.15%
controls:10.42%
12
75
503
5069
9
66
506
5078
5
12
510
5132
—
6
7
493
5123
13
76
413
4839
27
408
239
3509
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.5e-01
5.3e-01
1.4e+00
1.0e+50
2.2e+00
2.4e-01
1.2e-02
cases:3.69%
controls:2.62%
cases:3.50%
controls:2.08%
cases:1.36%
controls:0.35%
cases:1.36%
controls:0.00%
cases:2.00%
controls:0.23%
cases:3.76%
controls:2.97%
cases:18.80%
controls:18.61%
19
135
496
5009
18
107
497
5037
7
18
508
5126
7
0
508
5144
10
12
489
5118
16
146
410
4769
50
729
216
3188
Pertrochanteric fracture
S72.1 [45574361]
3.8e-01
—
2.3e+00
—
—
2.2e+00
4.8e-01
cases:1.17%
controls:0.80%
—
—
cases:0.97%
controls:0.10%
—
—
—
—
cases:2.58%
controls:0.31%
cases:2.26%
controls:1.40%
6
41
509
5103
—
5
5
510
5139
—
—
11
15
415
4900
6
55
260
3862
Extraction of multiple teeth
EBA15 [2001301927]
—
2.2e+00
—
—
—
—
1.3e+00
—
—
cases:1.17%
controls:0.14%
—
—
—
—
—
—
—
—
cases:2.63%
controls:0.71%
—
6
7
509
5137
—
—
—
—
7
28
259
3889
linagliptin; oral
A10BH05 [40251691]
2.2e+00
1.2e+00
—
—
—
—
1.7e-01
cases:1.17%
controls:0.14%
cases:0.97%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.63%
controls:2.22%
6
7
509
5137
5
15
510
5129
—
—
—
—
7
87
259
3830
Supplier / Service Provider
OMOP5117446 [33004]
-5.8e-01
—
-1.0e+50
—
—
—
2.1e+00
cases:6.99%
controls:11.86%
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
cases:3.38%
controls:0.41%
36
610
479
4534
—
0
11
515
5133
—
—
—
9
16
257
3901
Result test/procedure
-60 [2002000131]
9.8e-01
2.1e+00
—
—
—
1.0e+00
—
cases:1.94%
controls:0.74%
cases:1.94%
controls:0.23%
—
—
—
—
—
—
cases:1.17%
controls:0.43%
—
—
10
38
505
5106
10
12
505
5132
—
—
—
5
21
421
4894
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
3.1e-02
-1.7e-02
1.3e+00
1.0e+50
2.1e+00
5.0e-01
4.3e-01
cases:5.83%
controls:5.66%
cases:2.52%
controls:2.57%
cases:1.36%
controls:0.37%
cases:5.05%
controls:0.00%
cases:3.21%
controls:0.41%
cases:4.46%
controls:2.75%
cases:12.78%
controls:8.68%
30
291
485
4853
13
132
502
5012
7
19
508
5125
26
0
489
5144
16
21
483
5109
19
135
407
4780
34
340
232
3577
enoxaparin; parenteral
B01AB05 [21600976]
2.4e-01
-6.3e-02
—
—
2.1e+00
1.9e-01
-4.6e-01
cases:5.24%
controls:4.18%
cases:1.55%
controls:1.65%
—
—
—
—
cases:2.40%
controls:0.31%
cases:2.11%
controls:1.75%
cases:4.89%
controls:7.56%
27
215
488
4929
8
85
507
5059
—
—
12
16
487
5114
9
86
417
4829
13
296
253
3621
biperiden; oral, parenteral
N04AA02 [21604447]
2.0e+00
—
—
—
—
—
—
cases:1.17%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
509
5136
—
—
—
—
—
—
Syncope and collapse
R55 [45568141]
8.0e-01
1.2e+00
—
—
—
5.1e-01
4.5e-01
cases:4.66%
controls:2.16%
cases:2.52%
controls:0.76%
—
—
—
—
—
—
cases:1.41%
controls:0.85%
cases:5.26%
controls:3.42%
24
111
491
5033
13
39
502
5105
—
—
—
6
42
420
4873
14
134
252
3783
sertraline; oral
N06AB06 [21604714]
8.6e-01
2.0e+00
—
—
—
1.6e+00
9.8e-01
cases:1.55%
controls:0.66%
cases:2.14%
controls:0.29%
—
—
—
—
—
—
cases:1.64%
controls:0.33%
cases:1.88%
controls:0.71%
8
34
507
5110
11
15
504
5129
—
—
—
7
16
419
4899
5
28
261
3889
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
2.0e+00
—
—
—
—
-1.0e+50
6.0e-01
cases:1.36%
controls:0.19%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:2.63%
controls:1.46%
7
10
508
5134
—
—
—
—
0
10
426
4905
7
57
259
3860
Upper gastrointestinal surgery
106 [44777669]
2.3e-01
-2.8e-02
1.9e+00
—
8.1e-01
2.8e-01
-2.9e-01
cases:11.07%
controls:8.98%
cases:3.69%
controls:3.79%
cases:2.72%
controls:0.41%
—
—
cases:1.60%
controls:0.72%
cases:4.93%
controls:3.76%
cases:10.90%
controls:14.07%
57
462
458
4682
19
195
496
4949
14
21
501
5123
—
8
37
491
5093
21
185
405
4730
29
551
237
3366
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
2.5e-01
1.4e-01
—
—
1.9e+00
1.6e-01
-5.4e-01
cases:1.75%
controls:1.36%
cases:1.17%
controls:1.01%
—
—
—
—
cases:1.40%
controls:0.21%
cases:1.64%
controls:1.40%
cases:6.39%
controls:10.47%
9
70
506
5074
6
52
509
5092
—
—
7
11
492
5119
7
69
419
4846
17
410
249
3507
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-1.2e-03
4.0e-01
9.7e-01
—
1.8e+00
3.3e-01
1.8e-01
cases:4.47%
controls:4.47%
cases:6.02%
controls:4.12%
cases:2.91%
controls:1.13%
—
—
cases:5.21%
controls:0.86%
cases:8.45%
controls:6.25%
cases:34.21%
controls:30.28%
23
230
492
4914
31
212
484
4932
15
58
500
5086
—
26
44
473
5086
36
307
390
4608
91
1186
175
2731
Delirium, unspecified
F05.9 [45591078]
1.8e+00
—
—
—
—
-1.0e+50
—
cases:1.94%
controls:0.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
10
16
505
5128
—
—
—
—
0
9
426
4906
—
Outpatient Visit
OP [9202]
2.6e-01
1.9e-02
5.6e-03
3.0e+00
-9.8e-02
-2.5e-01
-1.2e+00
cases:78.83%
controls:74.22%
cases:51.84%
controls:51.38%
cases:12.82%
controls:12.75%
cases:11.46%
controls:0.62%
cases:11.82%
controls:12.88%
cases:47.89%
controls:54.10%
cases:64.29%
controls:85.70%
406
3818
109
1326
267
2643
248
2501
66
656
449
4488
59
32
456
5112
59
661
440
4469
204
2659
222
2256
171
3357
95
560
Disorientation, unspecified
R41.0 [45558469]
1.8e+00
1.9e+00
1.0e+50
—
—
1.5e+00
6.9e-01
cases:2.91%
controls:0.49%
cases:1.17%
controls:0.17%
cases:0.97%
controls:0.00%
—
—
—
—
cases:1.17%
controls:0.26%
cases:2.26%
controls:1.15%
15
25
500
5119
6
9
509
5135
5
0
510
5144
—
—
5
13
421
4902
6
45
260
3872
duloxetine; oral
N06AX21 [21604749]
8.8e-01
1.8e+00
—
—
—
—
6.9e-01
cases:2.14%
controls:0.89%
cases:2.33%
controls:0.39%
—
—
—
—
—
—
—
—
cases:2.26%
controls:1.15%
11
46
504
5098
12
20
503
5124
—
—
—
—
6
45
260
3872
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
3.2e-01
3.7e-01
—
—
1.8e+00
2.8e-01
-5.2e-02
cases:3.88%
controls:2.84%
cases:2.91%
controls:2.02%
—
—
—
—
cases:1.60%
controls:0.27%
cases:4.23%
controls:3.21%
cases:15.41%
controls:16.11%
20
146
495
4998
15
104
500
5040
—
—
8
14
491
5116
18
158
408
4757
41
631
225
3286
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
-9.7e-02
1.6e+00
1.0e+50
1.8e+00
5.8e-01
-1.1e-01
—
—
cases:0.97%
controls:1.07%
cases:1.55%
controls:0.33%
cases:1.36%
controls:0.00%
cases:1.60%
controls:0.27%
cases:1.88%
controls:1.06%
cases:4.89%
controls:5.41%
—
5
55
510
5089
8
17
507
5127
7
0
508
5144
8
14
491
5116
8
52
418
4863
13
212
253
3705
denosumab; parenteral
M05BX04 [21604169]
1.5e+00
1.8e+00
—
—
—
—
—
cases:0.97%
controls:0.21%
cases:1.36%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
5
11
510
5133
7
12
508
5132
—
—
—
—
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
9.7e-01
1.6e+00
—
—
—
1.8e+00
7.3e-02
cases:0.97%
controls:0.37%
cases:0.97%
controls:0.19%
—
—
—
—
—
—
cases:1.64%
controls:0.28%
cases:2.63%
controls:2.45%
5
19
510
5125
5
10
510
5134
—
—
—
7
14
419
4901
7
96
259
3821
Pain general/multiple sites
A01 [2002000142]
—
—
—
—
—
1.7e+00
7.3e-01
—
—
—
—
—
—
—
—
—
—
cases:2.11%
controls:0.39%
cases:3.38%
controls:1.66%
—
—
—
—
—
9
19
417
4896
9
65
257
3852
Oncology Clinic/Center
261QX0200X [38004268]
2.1e-02
-2.1e-01
1.5e+00
—
1.7e+00
-9.3e-01
-2.3e-01
cases:8.54%
controls:8.38%
cases:2.52%
controls:3.11%
cases:1.17%
controls:0.25%
—
—
cases:1.60%
controls:0.29%
cases:1.41%
controls:3.50%
cases:9.77%
controls:11.97%
44
431
471
4713
13
160
502
4984
6
13
509
5131
—
8
15
491
5115
6
172
420
4743
26
469
240
3448
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
4.8e-01
1.7e+00
—
—
—
3.3e-01
-1.0e-01
cases:3.88%
controls:2.45%
cases:4.08%
controls:0.78%
—
—
—
—
—
—
cases:1.41%
controls:1.02%
cases:4.51%
controls:4.98%
20
126
495
5018
21
40
494
5104
—
—
—
6
50
420
4865
12
195
254
3722
ergoloid mesylates; oral, parenteral
C04AE01 [21601580]
1.7e+00
—
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:2.14%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.31%
11
21
504
5123
—
—
—
0
5
499
5125
0
12
426
4903
0
12
266
3905
calcium (different salts in combination); oral
A12AA20 [21600872]
5.5e-01
5.6e-01
7.2e-01
-1.0e+50
1.8e-01
4.6e-01
2.3e-01
cases:19.81%
controls:12.42%
cases:17.48%
controls:10.75%
cases:5.24%
controls:2.62%
cases:0.00%
controls:0.10%
cases:3.01%
controls:2.51%
cases:17.84%
controls:12.02%
cases:25.19%
controls:21.16%
102
639
413
4505
90
553
425
4591
27
135
488
5009
0
5
515
5139
15
129
484
5001
76
591
350
4324
67
829
199
3088
Heart failure, unspecified
I50.9 [45576879]
3.3e-01
3.4e-01
1.6e+00
—
1.2e+00
1.9e-01
-2.2e-01
cases:7.18%
controls:5.25%
cases:4.47%
controls:3.23%
cases:3.30%
controls:0.70%
—
—
cases:2.00%
controls:0.62%
cases:5.40%
controls:4.50%
cases:11.65%
controls:14.12%
37
270
478
4874
23
166
492
4978
17
36
498
5108
—
10
32
489
5098
23
221
403
4694
31
553
235
3364
Medical examin/health eval partial
-31 [2002000102]
6.8e-01
1.5e+00
—
—
-1.0e+50
—
—
cases:1.75%
controls:0.89%
cases:2.33%
controls:0.51%
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
9
46
506
5098
12
26
503
5118
—
—
0
5
499
5125
—
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
3.2e-01
4.7e-01
1.1e+00
—
1.5e+00
3.7e-01
5.1e-01
cases:12.04%
controls:9.00%
cases:5.83%
controls:3.71%
cases:0.97%
controls:0.31%
—
—
cases:1.80%
controls:0.39%
cases:5.16%
controls:3.62%
cases:19.55%
controls:12.74%
62
463
453
4681
30
191
485
4953
5
16
510
5128
—
9
20
490
5110
22
178
404
4737
52
499
214
3418
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
5.0e-01
1.5e+00
—
—
—
6.9e-01
-1.5e-01
cases:1.75%
controls:1.07%
cases:2.72%
controls:0.62%
—
—
—
—
—
—
cases:1.64%
controls:0.83%
cases:7.14%
controls:8.20%
9
55
506
5089
14
32
501
5112
—
—
—
7
41
419
4874
19
321
247
3596
colecalciferol; oral
A11CC05 [21600820]
—
1.8e+00
—
—
—
—
1.5e+00
—
—
cases:0.97%
controls:0.16%
—
—
—
—
—
—
—
—
cases:3.76%
controls:0.87%
—
5
8
510
5136
—
—
—
—
10
34
256
3883
pivmecillinam; oral
J01CA08 [21602827]
2.5e-01
7.4e-01
1.1e+00
—
2.0e-01
1.7e-01
7.4e-01
cases:15.92%
controls:12.91%
cases:11.26%
controls:5.70%
cases:2.33%
controls:0.76%
—
—
cases:1.00%
controls:0.82%
cases:7.51%
controls:6.39%
cases:27.82%
controls:15.50%
82
664
433
4480
58
293
457
4851
12
39
503
5105
—
5
42
494
5088
32
314
394
4601
74
607
192
3310
Assessment of need for oral health care, standard
SAD01 [2001310287]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:4.89%
controls:1.20%
—
0
11
515
5133
—
—
—
—
13
47
253
3870
chlorhexidine
S02AA09 [21605155]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
chlorhexidine
D09AA12 [21602275]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
chlorhexidine, combinations
D08AC52 [21602208]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
hydrocortisone
D07XA01 [21602180]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
chlorhexidine
S03AA04 [21605193]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
hydrocortisone and antiseptics
D07BA04 [21602146]
-1.5e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.26%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.63%
cases:3.01%
controls:2.53%
10
116
505
5028
—
—
—
—
11
31
415
4884
8
99
258
3818
triamcinolone and antiseptics
D07BB03 [21602150]
-2.6e-01
—
—
—
—
1.4e+00
1.8e-01
cases:1.94%
controls:2.51%
—
—
—
—
—
—
—
—
cases:2.58%
controls:0.65%
cases:3.01%
controls:2.53%
10
129
505
5015
—
—
—
—
11
32
415
4883
8
99
258
3818
Concussion
S06.0 [45582805]
1.0e+00
9.6e-01
—
1.0e+50
—
1.4e+00
1.0e+00
cases:2.52%
controls:0.93%
cases:1.17%
controls:0.45%
—
—
cases:1.17%
controls:0.00%
—
—
cases:2.35%
controls:0.61%
cases:4.51%
controls:1.63%
13
48
502
5096
6
23
509
5121
—
6
0
509
5144
—
10
30
416
4885
12
64
254
3853
Orthopedic Surgery
20 [38004465]
2.0e-01
2.1e-01
1.4e+00
—
3.6e-01
4.5e-01
-5.5e-02
cases:16.12%
controls:13.63%
cases:6.41%
controls:5.25%
cases:3.30%
controls:0.87%
—
—
cases:1.00%
controls:0.70%
cases:7.51%
controls:4.90%
cases:16.17%
controls:16.93%
83
701
432
4443
33
270
482
4874
17
45
498
5099
—
5
36
494
5094
32
241
394
4674
43
663
223
3254
Acute cystitis
N30.0 [45601724]
8.4e-01
8.0e-01
2.3e+00
—
-1.0e+50
1.3e+00
6.7e-01
cases:3.69%
controls:1.63%
cases:2.14%
controls:0.97%
cases:0.97%
controls:0.10%
—
—
cases:0.00%
controls:0.10%
cases:3.52%
controls:0.96%
cases:7.89%
controls:4.19%
19
84
496
5060
11
50
504
5094
5
5
510
5139
—
0
5
499
5125
15
47
411
4868
21
164
245
3753
Incontinence urine
U04 [2002001139]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.89%
controls:1.38%
—
—
—
—
—
—
13
54
253
3863
Bacterial infection, unspecified
A49.9 [45590816]
6.9e-01
9.8e-01
—
1.0e+50
—
1.3e+00
4.1e-01
cases:2.52%
controls:1.28%
cases:1.75%
controls:0.66%
—
—
cases:1.36%
controls:0.00%
—
—
cases:2.82%
controls:0.81%
cases:5.64%
controls:3.83%
13
66
502
5078
9
34
506
5110
—
7
0
508
5144
—
12
40
414
4875
15
150
251
3767
Essential (primary) hypertension
I10 [45591453]
2.5e-02
2.4e-01
1.2e+00
—
8.6e-01
-1.3e-01
-8.5e-01
cases:23.50%
controls:23.06%
cases:14.95%
controls:12.15%
cases:5.44%
controls:1.75%
—
—
cases:5.01%
controls:2.18%
cases:12.91%
controls:14.38%
cases:22.93%
controls:40.95%
121
1186
394
3958
77
625
438
4519
28
90
487
5054
—
25
112
474
5018
55
707
371
4208
61
1604
205
2313
Primary partial prosthetic replacement of hip joint using cement, other or unspecified
NFB20 [2001307920]
1.2e+00
—
—
—
—
—
7.6e-01
cases:2.72%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
cases:3.01%
controls:1.43%
14
44
501
5100
—
—
—
—
—
8
56
258
3861
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
4.5e-01
—
—
—
7.6e-01
1.1e+00
—
—
cases:0.97%
controls:0.62%
—
—
—
—
—
—
cases:1.64%
controls:0.77%
cases:6.02%
controls:1.99%
—
5
32
510
5112
—
—
—
7
38
419
4877
16
78
250
3839
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-7.0e-02
-5.9e-02
4.4e-01
—
1.1e+00
-6.0e-02
-2.8e-01
cases:4.85%
controls:5.19%
cases:4.85%
controls:5.13%
cases:1.75%
controls:1.13%
—
—
cases:2.81%
controls:0.92%
cases:7.04%
controls:7.45%
cases:26.69%
controls:32.52%
25
267
490
4877
25
264
490
4880
9
58
506
5086
—
14
47
485
5083
30
366
396
4549
71
1274
195
2643
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
1.1e+00
—
—
—
-1.0e+50
—
—
cases:2.52%
controls:0.84%
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
13
43
502
5101
—
—
—
0
5
499
5125
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.1e+00
1.2e+00
1.8e+00
—
—
6.3e-01
3.6e-01
cases:2.52%
controls:0.86%
cases:2.14%
controls:0.68%
cases:0.97%
controls:0.16%
—
—
—
—
cases:2.11%
controls:1.14%
cases:10.53%
controls:7.56%
13
44
502
5100
11
35
504
5109
5
8
510
5136
—
—
9
56
417
4859
28
296
238
3621
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-4.1e-01
-1.0e-01
2.1e-01
—
1.1e+00
-2.4e-02
-2.0e-01
cases:2.91%
controls:4.32%
cases:4.47%
controls:4.92%
cases:1.94%
controls:1.57%
—
—
cases:3.21%
controls:1.11%
cases:6.81%
controls:6.96%
cases:25.19%
controls:29.21%
15
222
500
4922
23
253
492
4891
10
81
505
5063
—
16
57
483
5073
29
342
397
4573
67
1144
199
2773
norfloxacin; oral
J01MA06 [21603013]
1.9e-01
1.1e+00
—
—
—
—
4.9e-01
cases:4.85%
controls:4.06%
cases:3.11%
controls:1.09%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.58%
25
209
490
4935
16
56
499
5088
—
—
—
—
11
101
255
3816
nystatin
D01AA01 [21601911]
1.1e+00
—
—
—
—
—
—
cases:2.91%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
15
53
500
5091
—
—
—
—
—
—
metronidazole and furazolidone
P01AB51 [45893518]
1.1e+00
—
—
—
—
—
—
cases:2.91%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
15
53
500
5091
—
—
—
—
—
—
nystatin; vaginal
G01AA01 [21602363]
1.1e+00
—
—
—
—
—
—
cases:2.91%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
15
53
500
5091
—
—
—
—
—
—
Exposure to unspecified factor
X59 [45756412]
1.0e+00
9.9e-01
—
—
-1.0e+50
—
7.1e-03
cases:4.66%
controls:1.71%
cases:1.55%
controls:0.58%
—
—
—
—
cases:0.00%
controls:0.18%
—
—
cases:3.01%
controls:2.99%
24
88
491
5056
8
30
507
5114
—
—
0
9
499
5121
—
8
117
258
3800
Fever, unspecified
R50.9 [45582716]
8.3e-01
1.1e+00
—
—
—
6.1e-01
1.0e+00
cases:2.72%
controls:1.21%
cases:1.55%
controls:0.54%
—
—
—
—
—
—
cases:1.41%
controls:0.77%
cases:6.39%
controls:2.40%
14
62
501
5082
8
28
507
5116
—
—
—
6
38
420
4877
17
94
249
3823
melatonin; oral
N05CH01 [21604659]
1.3e+00
1.1e+00
2.1e+00
—
—
1.3e+00
9.7e-01
cases:1.17%
controls:0.31%
cases:1.36%
controls:0.47%
cases:0.97%
controls:0.12%
—
—
—
—
cases:2.11%
controls:0.59%
cases:7.89%
controls:3.14%
6
16
509
5128
7
24
508
5120
5
6
510
5138
—
—
9
29
417
4886
21
123
245
3794
Fracture of neck of femur
S72.0 [45593656]
9.4e-01
9.8e-01
—
1.0e+50
—
1.2e+00
6.8e-01
cases:3.69%
controls:1.48%
cases:1.75%
controls:0.66%
—
—
cases:0.97%
controls:0.00%
—
—
cases:2.35%
controls:0.73%
cases:4.89%
controls:2.53%
19
76
496
5068
9
34
506
5110
—
5
0
510
5144
—
10
36
416
4879
13
99
253
3818
oxycodone; oral, parenteral
N02AA05 [21604260]
2.7e-01
2.8e-01
1.1e+00
—
—
5.9e-01
8.9e-01
cases:1.75%
controls:1.34%
cases:1.36%
controls:1.03%
cases:0.97%
controls:0.33%
—
—
—
—
cases:2.58%
controls:1.44%
cases:10.90%
controls:4.77%
9
69
506
5075
7
53
508
5091
5
17
510
5127
—
—
11
71
415
4844
29
187
237
3730
Preventive oral health care, short
SCA01 [2001310302]
—
7.8e-01
—
—
-1.0e+50
—
8.8e-01
—
—
cases:0.97%
controls:0.45%
—
—
—
—
cases:0.00%
controls:0.12%
—
—
cases:6.77%
controls:2.91%
—
5
23
510
5121
—
—
0
6
499
5124
—
18
114
248
3803
Handing over of treatment supplies
SPAT1262 [2001700363]
8.5e-01
8.4e-01
8.3e-01
—
—
5.0e-01
3.3e-01
cases:4.27%
controls:1.87%
cases:3.88%
controls:1.71%
cases:0.97%
controls:0.43%
—
—
—
—
cases:3.52%
controls:2.16%
cases:9.77%
controls:7.20%
22
96
493
5048
20
88
495
5056
5
22
510
5122
—
—
15
106
411
4809
26
282
240
3635
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
4.1e-01
2.7e-01
4.4e-01
-1.0e+50
5.5e-01
4.4e-01
1.7e-01
cases:38.45%
controls:29.34%
cases:26.80%
controls:21.79%
cases:8.16%
controls:5.38%
cases:0.00%
controls:0.14%
cases:8.42%
controls:5.03%
cases:33.80%
controls:24.72%
cases:57.14%
controls:52.85%
198
1509
317
3635
138
1121
377
4023
42
277
473
4867
0
7
515
5137
42
258
457
4872
144
1215
282
3700
152
2070
114
1847
Other specified special examinations
Z01.8 [45581003]
8.1e-01
6.2e-01
—
—
—
—
-7.8e-02
cases:4.85%
controls:2.22%
cases:1.36%
controls:0.74%
—
—
—
—
—
—
—
—
cases:3.01%
controls:3.24%
25
114
490
5030
7
38
508
5106
—
—
—
—
8
127
258
3790
insulin glargine; parenteral
A10AE04 [21600739]
7.8e-01
4.2e-01
7.9e-01
—
2.5e-01
1.4e-01
9.4e-02
cases:5.24%
controls:2.47%
cases:4.47%
controls:2.99%
cases:1.75%
controls:0.80%
—
—
cases:1.00%
controls:0.78%
cases:3.76%
controls:3.28%
cases:5.64%
controls:5.16%
27
127
488
5017
23
154
492
4990
9
41
506
5103
—
5
40
494
5090
16
161
410
4754
15
202
251
3715
insulin (beef); parenteral
A10AD02 [21600730]
7.8e-01
4.2e-01
7.9e-01
—
2.5e-01
1.4e-01
9.4e-02
cases:5.24%
controls:2.47%
cases:4.47%
controls:2.99%
cases:1.75%
controls:0.80%
—
—
cases:1.00%
controls:0.78%
cases:3.76%
controls:3.28%
cases:5.64%
controls:5.16%
27
127
488
5017
23
154
492
4990
9
41
506
5103
—
5
40
494
5090
16
161
410
4754
15
202
251
3715
trimethoprim; oral, parenteral
J01EA01 [21602931]
4.4e-01
-5.7e-02
5.6e-01
—
8.7e-01
3.6e-01
6.0e-01
cases:12.62%
controls:8.53%
cases:4.27%
controls:4.51%
cases:1.36%
controls:0.78%
—
—
cases:1.80%
controls:0.76%
cases:6.57%
controls:4.66%
cases:19.92%
controls:11.97%
65
439
450
4705
22
232
493
4912
7
40
508
5104
—
9
39
490
5091
28
229
398
4686
53
469
213
3448
temazepam; oral
N05CD07 [21604642]
5.1e-01
3.9e-01
5.1e-01
—
3.1e-01
8.2e-02
3.8e-01
cases:12.43%
controls:7.85%
cases:8.54%
controls:5.95%
cases:2.52%
controls:1.54%
—
—
cases:1.80%
controls:1.33%
cases:6.81%
controls:6.31%
cases:12.41%
controls:8.83%
64
404
451
4740
44
306
471
4838
13
79
502
5065
—
9
68
490
5062
29
310
397
4605
33
346
233
3571
Cystoscopy and bladder biopsy
UKC05 [2001306006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
266
3909
Internal fixation of fracture of ankle using wire, rod, cerclage or pin
NHJ10 [2001308333]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
0
6
426
4909
—
Tingling fingers/feet/toes
N05 [2002000723]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Gastrointestinal haemorrhage, unspecified
K92.2 [45533625]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:0.00%
controls:0.22%
cases:0.00%
controls:0.51%
—
0
6
515
5138
—
—
—
0
11
426
4904
0
20
266
3897
Diabetes, non-insulin-treated
215 [2001600211]
6.1e-02
—
—
—
—
-1.0e+50
1.4e-03
cases:0.97%
controls:0.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
cases:6.39%
controls:6.38%
5
47
510
5097
—
—
—
—
0
15
426
4900
17
250
249
3667
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
cases:0.00%
controls:0.66%
0
6
515
5138
—
—
—
—
0
6
426
4909
0
26
266
3891
Unspecified lump in breast
N63 [45601743]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
515
5132
—
—
—
—
—
—
Pneumonia, organism unspecified
J18 [45548107]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
Rehabilitation for hearing problems
R4135 [2001310236]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:1.15%
—
0
10
515
5134
—
—
—
0
17
426
4898
0
45
266
3872
loratadine; oral
R06AX13 [21603514]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.33%
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.46%
—
0
17
515
5127
—
—
0
5
499
5125
0
17
426
4898
0
18
266
3899
Uroflowmetry
44856007 [4261340]
1.5e-01
-4.6e-01
—
—
—
-5.4e-02
-7.2e-01
cases:4.66%
controls:4.02%
cases:0.97%
controls:1.54%
—
—
—
—
—
—
cases:1.41%
controls:1.49%
cases:2.63%
controls:5.26%
24
207
491
4937
5
79
510
5065
—
—
—
6
73
420
4842
7
206
259
3711
Pressure/tightness of heart
K02 [2002000545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
12
266
3905
Other chronic obstructive pulmonary disease
J44 [45543268]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:1.56%
—
0
21
515
5123
—
—
—
0
22
426
4893
0
61
266
3856
Cellulitis of finger and toe
L03.0 [45557691]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
0
5
515
5139
—
—
—
—
—
Toothache NOS
K08.80 [2000502799]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
14
266
3903
Other autoimmune haemolytic anaemias
D59.1 [45566703]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
fosfomycin; oral, parenteral
J01XX01 [21603061]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—
Glaucoma suspect
H40.0 [45567051]
1.7e-01
—
—
—
—
—
—
cases:1.36%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
7
59
508
5085
—
—
—
—
—
—
Examination and observation for unspecified reason
Z04.9 [45605102]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
—
0
10
426
4905
—
Patch test
41778007 [4218642]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
515
5134
—
—
—
—
—
—
Seborrhoea capitis
L21.0 [45586766]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—
Transurethral incision of prostate
KED33 [2001306139]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.25%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
0
13
515
5131
—
—
—
—
—
0
8
266
3909
CT examination of brain pefusion
AA5PD [2001300195]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
266
3909
Thyroid insufficiency
104 [2001600104]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
266
3909
Electrophysiological examination of eye
XCD10 [2001300413]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.66%
—
—
—
—
—
0
10
426
4905
0
26
266
3891
Metabolic, Other reason for encounter NEC
T69 [2002001117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—
methotrexate
L01BA01 [21601423]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
17
515
5127
—
0
16
499
5114
—
—
Presence of prosthetic heart valve
Z95.2 [45542495]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
0
7
515
5137
—
—
—
0
8
426
4907
—
Multiple myeloma
C90.0 [45600562]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
16
266
3901
Tension-type headache
G44.2 [45581495]
3.8e-01
—
—
—
—
-1.0e+50
-1.0e+50
cases:1.17%
controls:0.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.17%
6
41
509
5103
—
—
—
—
0
25
426
4890
0
46
266
3871
pegfilgrastim; parenteral
L03AA13 [21603856]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
0
5
515
5139
—
—
—
—
0
11
266
3906
Diverticulum of oesophagus, acquired
K22.5 [45572199]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
Physiotherapist
Z3226 [2001311560]
-3.8e-01
-1.3e-01
—
—
—
-6.1e-01
—
cases:2.91%
controls:4.22%
cases:1.75%
controls:1.98%
—
—
—
—
—
—
cases:1.17%
controls:2.14%
—
—
15
217
500
4927
9
102
506
5042
—
—
—
5
105
421
4810
—
Lymphocytes/Leukocytes in Synovial fluid
26483-8 [3003329]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
scopolamine; oral, parenteral
N05CM05 [21604666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Gas panel - Venous blood
24339-4 [3000991]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
0
12
515
5132
—
—
—
—
0
13
426
4902
—
Sarcoidosis of lung
D86.0 [45576422]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
0
12
515
5132
—
—
—
—
0
5
426
4910
—
Percutaneous transluminal coronary angioplasty (PTCA), drug-eluting balloon
FN2AB [2001303089]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
Otalgia
H92.0 [45596177]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
0
6
515
5138
—
—
—
—
0
10
266
3907
Insertion of central venous catheter through subclavian or brachiocephalic vein
TPH20 [2001309601]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
cases:0.00%
controls:0.15%
—
—
—
—
—
0
7
426
4908
0
6
266
3911
azelastine; nasal
R01AC03 [21605035]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
515
5129
—
—
—
—
—
—
Streptococcus pneumoniae Ag [Presence] in Urine
24027-5 [3011363]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
chloramphenicol
S03AA08 [21605197]
3.4e-02
4.5e-01
—
—
-1.0e+50
8.6e-02
5.8e-02
cases:2.33%
controls:2.26%
cases:0.97%
controls:0.62%
—
—
—
—
cases:0.00%
controls:0.14%
cases:1.17%
controls:1.08%
cases:6.77%
controls:6.41%
12
116
503
5028
5
32
510
5112
—
—
0
7
499
5123
5
53
421
4862
18
251
248
3666
pneumococcus, purified polysaccharides antigen
J07AL01 [21601312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
17
266
3900
dexrabeprazole
A02BC07 [45893509]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
0
5
515
5139
—
—
—
—
Primary total prosthetic replacement of hip joint not using cement
NFB30 [2001307921]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
26
266
3891
Other and unspecified convulsions
R56.8 [45602033]
9.2e-01
1.7e+00
—
—
—
—
—
cases:0.97%
controls:0.39%
cases:0.97%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
5
20
510
5124
5
9
510
5135
—
—
—
—
—
Other hearing loss
H91 [45581753]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
eprosartan and diuretics
C09DA02 [21601835]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
0
6
426
4909
—
acrivastine; oral
R06AX18 [21603518]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
0
55
266
3862
Malignant melanoma of skin
C43 [45571501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
bismuth subnitrate
A02BX12 [21600121]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—
Discission of sheath of tendon of wrist or hand
NDM40 [2001307726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—
General and Unspecified, Other reason for encounter NEC
A69 [2002000203]
1.6e+00
8.4e-01
-1.0e+50
—
-1.0e+50
—
—
cases:1.36%
controls:0.27%
cases:1.17%
controls:0.51%
cases:0.00%
controls:0.14%
—
—
cases:0.00%
controls:0.14%
—
—
—
—
7
14
508
5130
6
26
509
5118
0
7
515
5137
—
0
7
499
5123
—
—
Rectal polyp
K62.1 [45586728]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Metabolic, Observ/health educat/advice/diet
T45 [2002001093]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.17%
cases:0.00%
controls:0.10%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
cases:0.00%
controls:0.38%
0
9
515
5135
0
5
515
5139
—
—
—
0
10
426
4905
0
15
266
3902
Rash generalized
S07 [2002000972]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Root filling of tooth with one root canal
SGB10 [2001310388]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
15
515
5129
—
—
—
—
—
Other seborrhoeic dermatitis
L21.8 [45548192]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
0
5
426
4910
—
Benign paroxysmal vertigo
H81.1 [45572061]
4.7e-01
—
—
—
—
-1.0e+50
—
cases:1.36%
controls:0.86%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
7
44
508
5100
—
—
—
—
0
18
426
4897
—
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
-1.3e-01
5.0e-01
—
—
—
1.6e-01
-1.7e-01
cases:1.75%
controls:1.98%
cases:1.75%
controls:1.07%
—
—
—
—
—
—
cases:1.41%
controls:1.20%
cases:3.01%
controls:3.55%
9
102
506
5042
9
55
506
5089
—
—
—
6
59
420
4856
8
139
258
3778
hydrocortisone and antiinfectives
S01CA03 [21603654]
1.1e-01
—
—
—
-1.0e+50
—
3.3e-01
cases:1.17%
controls:1.05%
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
cases:1.88%
controls:1.35%
6
54
509
5090
—
—
—
0
6
499
5124
—
5
53
261
3864
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
-1.0e+50
—
—
—
—
—
6.0e-01
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.32%
0
21
515
5123
—
—
—
—
—
11
91
255
3826
Benign tumor of the meninges at the base of the brain
D32.02 [2000501309]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
0
5
515
5139
—
—
—
—
—
0
5
266
3912
Tympanometry
SPAT1044 [2001700145]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
8
266
3909
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.51%
—
0
9
515
5135
—
—
—
0
8
426
4907
0
20
266
3897
Hallux valgus (acquired)
M20.1 [45606152]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
0
7
515
5137
—
—
—
0
13
426
4902
—
Physiologic investigation of micturition
XKD06 [2001306098]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
—
—
—
—
—
0
9
515
5135
—
—
—
—
—
Thoracoabdominal aortic aneurysm, without mention of rupture
I71.6 [45533496]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
515
5139
—
—
—
—
—
—
Benign neoplasm: Parotid gland
D11.0 [45571596]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
515
5132
—
—
—
—
—
—
Extensive CT of aorta
PD5BD [2001309001]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.31%
—
—
—
—
—
—
cases:0.00%
controls:0.14%
cases:0.00%
controls:0.66%
0
11
515
5133
0
16
515
5128
—
—
—
0
7
426
4908
0
26
266
3891
Diplopia
H53.2 [45576792]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.56%
—
—
—
—
—
0
5
426
4910
0
22
266
3895
Other specified pleural conditions
J94.8 [45567278]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.51%
0
11
515
5133
—
—
—
—
0
8
426
4907
0
20
266
3897
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.4 [45572067]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
cases:0.00%
controls:0.23%
—
—
—
—
—
0
6
426
4909
0
9
266
3908
More than three and less than five hours
ZXE20 [2001311408]
-6.0e-01
—
—
—
—
—
-1.0e+50
cases:1.17%
controls:2.10%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.81%
6
108
509
5036
—
—
—
—
—
0
110
266
3807
Intravenous administration of medicine
SPAT1255 [2001700356]
—
—
—
—
—
—
5.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.01%
controls:1.71%
—
—
—
—
—
—
8
67
258
3850
pH of Arterial blood
2744-1 [3019977]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-3.3e-01
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:1.88%
controls:2.60%
0
17
515
5127
0
10
515
5134
—
—
—
0
17
426
4898
5
102
261
3815
Other angina pectoris unspecified coronary artery status
I20.89 [2000502401]
-5.1e-02
—
—
—
—
-1.0e+50
—
cases:1.17%
controls:1.22%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
6
63
509
5081
—
—
—
—
0
8
426
4907
—
indometacin
C01EB03 [21600365]
3.6e-01
—
-1.0e+50
—
—
—
-1.0e+50
cases:2.14%
controls:1.50%
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
11
77
504
5067
—
0
6
515
5138
—
—
—
0
38
266
3879
Respiratory, Preventive immunization/medic
R44 [2002000913]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
515
5134
—
—
—
—
—
—
Swelling
A08 [2002000149]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.19%
cases:0.00%
controls:0.14%
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
0
10
515
5134
0
7
515
5137
—
—
—
0
10
426
4905
—
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
0
17
266
3900
Initial pacemaker installation
73 [2002100123]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
515
5124
—
—
—
—
—
—
Urinary tract cathetrisation with X-ray guidance
KH1BT [2001305794]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
Valveoplasty of the aortic valve
AP6 [2000200180]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Cauterisation of mucosa of nose
DKW00 [2001301715]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
0
6
515
5138
—
—
—
—
—
0
6
266
3911
tolfenamic acid; oral, rectal
M01AG02 [21603988]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
9
266
3908
Atrioventricular block, first degree
I44.0 [45543176]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
0
7
515
5137
—
—
—
—
0
15
266
3902
GD
GD1LA [2001303643]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
Phlebitis and thrombophlebitis of superficial vessels of lower extremities
I80.0 [45576919]
1.0e+00
—
—
—
—
—
-1.0e+50
cases:0.97%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
5
18
510
5126
—
—
—
—
—
0
17
266
3900
Superficial injury of other parts of head
S00.8 [45563349]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
7
266
3910
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
0
6
515
5138
—
—
—
—
0
7
426
4908
—
Other allergic rhinitis
J30.3 [45538477]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
515
5139
—
—
—
—
—
—
Telehealth
OMOP5556618 [722455]
-6.3e-02
6.6e-02
-1.1e-01
—
1.4e-01
5.5e-02
-2.0e-01
cases:9.90%
controls:10.48%
cases:11.07%
controls:10.44%
cases:2.52%
controls:2.82%
—
—
cases:3.01%
controls:2.61%
cases:13.15%
controls:12.53%
cases:31.95%
controls:36.53%
51
539
464
4605
57
537
458
4607
13
145
502
4999
—
15
134
484
4996
56
616
370
4299
85
1431
181
2486
Laser trabeculoplasty
CHD00 [2001301264]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.28%
—
0
7
515
5137
—
—
—
—
0
11
266
3906
platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]
1.6e-01
1.4e-01
-6.6e-02
—
—
-1.9e-01
5.3e-02
cases:4.66%
controls:3.99%
cases:4.08%
controls:3.56%
cases:1.17%
controls:1.24%
—
—
—
—
cases:3.05%
controls:3.68%
cases:5.26%
controls:5.00%
24
205
491
4939
21
183
494
4961
6
64
509
5080
—
—
13
181
413
4734
14
196
252
3721
Microbiological examinations
SBA00 [2001310293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
515
5139
—
—
—
—
—
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
0
7
426
4908
—
Atrial fibrillation/flutter
K78 [2002000605]
-2.7e-01
2.4e-01
—
—
—
8.0e-02
-8.7e-02
cases:0.97%
controls:1.26%
cases:1.75%
controls:1.38%
—
—
—
—
—
—
cases:2.11%
controls:1.95%
cases:4.89%
controls:5.31%
5
65
510
5079
9
71
506
5073
—
—
—
9
96
417
4819
13
208
253
3709
Malignant tumor of sigmoid carcinoma of adenoma
C18.72 [2000500564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
carvedilol; oral
C07AG02 [21601700]
-8.5e-01
—
—
—
-1.0e+50
—
—
cases:1.17%
controls:2.68%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
6
138
509
5006
—
—
—
0
28
499
5102
—
—
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
1.1e-01
—
—
—
—
—
-4.1e-01
cases:1.17%
controls:1.05%
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:2.81%
6
54
509
5090
—
—
—
—
—
5
110
261
3807
Chronic obstructive pulmonary disease, unspecified
J44.9 [45548115]
-3.7e-01
—
—
—
—
5.3e-01
—
cases:0.97%
controls:1.40%
—
—
—
—
—
—
—
—
cases:1.41%
controls:0.83%
—
—
5
72
510
5072
—
—
—
—
6
41
420
4874
—
Shoulder extensive X-ray examination without contrast
NB1BA [2001307228]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
13
266
3904
Skin injury other
S19 [2002000984]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
8
426
4907
0
30
266
3887
Counselling, unspecified
Z71.9 [45561648]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
0
8
515
5136
—
—
—
—
—
Dermatitis, unspecified
L30.9 [45572271]
-1.8e-02
—
—
—
-1.0e+50
-1.0e+50
—
cases:1.17%
controls:1.19%
—
—
—
—
—
—
cases:0.00%
controls:0.10%
cases:0.00%
controls:0.47%
—
—
6
61
509
5083
—
—
—
0
5
499
5125
0
23
426
4892
—
Laparoscopic repair of inguinal hernia
JAB11 [2001304390]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
-1.9e-01
—
—
—
—
—
8.0e-01
cases:1.36%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
cases:2.63%
controls:1.20%
7
84
508
5060
—
—
—
—
—
7
47
259
3870
Cataract, unspecified
H26.9 [45605651]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
0
8
515
5136
—
—
—
—
—
0
7
266
3910
Endocr/metab/nutrit disease other
T99 [2002001135]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
5
266
3912
Mantle cell lymphoma
C83.1 [45542646]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
Arthroplasty of first tarsometatarsal joint
NHG70 [2001308319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.14%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
515
5137
—
—
—
—
—
—
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
6
266
3911
Shoulder X-ray examination without contrast
NB1AA [2001307225]
1.0e+00
—
—
—
—
—
4.6e-01
cases:1.17%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:1.88%
controls:1.20%
6
22
509
5122
—
—
—
—
—
5
47
261
3870
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
15
266
3902
fondaparinux; parenteral
B01AX05 [21601030]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
515
5133
—
—
—
—
—
—
Presence of intraocular lens
Z96.1 [45585885]
-1.8e-01
-8.5e-02
—
—
-1.0e+50
—
-6.0e-01
cases:4.85%
controls:5.73%
cases:1.36%
controls:1.48%
—
—
—
—
cases:0.00%
controls:0.27%
—
—
cases:3.38%
controls:6.03%
25
295
490
4849
7
76
508
5068
—
—
0
14
499
5116
—
9
236
257
3681
Primary degenerative dementia of the Alzheimer's type, presenile onset information on additional symptoms is lacking and Alzheimer disease with early onset
F00.09*G30.0 [2000503816]
1.0e+50
1.0e+50
—
—
—
1.0e+50
1.0e+50
cases:1.94%
controls:0.00%
cases:2.72%
controls:0.00%
—
—
—
—
—
—
cases:4.69%
controls:0.00%
cases:2.26%
controls:0.00%
10
0
505
5144
14
0
501
5144
—
—
—
20
0
406
4915
6
0
260
3917
Traumatic subarachnoid haemorrhage
S06.6 [45587622]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
0
6
426
4909
—
fluorometholone
S01BA07 [21603624]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
0
22
515
5122
—
—
—
—
0
11
426
4904
—
Palpitations
R00.2 [45558446]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
0
8
515
5136
—
—
—
—
0
20
266
3897
Keratitis, unspecified
H16.9 [45605629]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
515
5138
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
75
1967
0.28
25.48
3.2
5.3
2.20
2.31
mmol/l
0.58
55
1688
70
1884
0.27
24.63
3.0
4.6
4.04
4.15
mmol/l
0.52
53
1627
70
1861
0.28
23.85
2.9
4.5
1.33
1.40
mmol/l
0.70
53
1588
68
1791
0.29
22.31
2.6
3.9
1.43
1.21
mmol/l
1.19
51
1510
98
2031
0.36
18.88
6.4
5.3
6.78
6.25
mmol/l
1.28
65
1733
43
1336
0.26
17.90
7.0
6.6
4.74
4.69
e9/l
0.03
35
1127
31
1161
0.22
17.52
3.4
4.4
0.58
0.66
e9/l
0.83
26
969
99
1995
0.38
17.44
6.8
7.2
47.37
42.02
mmol/mol
2.51
75
1761
32
1169
0.23
17.35
3.3
4.4
0.04
0.04
e9/l
0.38
27
978
35
1205
0.24
17.20
4.0
4.5
0.16
0.19
e9/l
0.57
29
1013
35
1200
0.24
17.06
3.3
4.7
1.53
1.64
e9/l
0.60
28
1036
64
1528
0.34
15.77
5.0
5.5
1.22
1.21
mmol/l
0.26
45
1260
101
1922
0.41
14.70
4.7
6.5
88.72
87.05
u/l
0.10
83
1779
78
1651
0.38
14.52
4.1
4.5
7.89
7.03
mmol/l
1.96
71
1565
35
1106
0.27
14.41
2.9
3.0
128.21
151.35
ug/l
0.44
29
984
50
1303
0.32
14.39
2.2
2.4
99.27
89.98
pmol/l
0.92
23
711
132
2248
0.45
14.35
6.4
10.8
19.62
23.41
u/l
1.38
109
2132
107
1974
0.42
14.28
3.8
5.0
2.05
2.16
mu/l
0.28
82
1716
60
1421
0.35
14.18
4.5
4.8
12.24
13.67
umol/l
0.36
51
1334
80
1618
0.40
13.01
3.4
3.9
15.30
15.40
pmol/l
0.13
64
1404
54
1300
0.35
12.96
3.1
3.7
3176.44
3251.30
ng/l
0.03
41
1141
57
1318
0.36
12.45
4.2
5.2
1.22
1.21
mmol/l
0.54
50
1173
37
1005
0.32
11.05
12.7
13.4
0.00
0.01
e9/l
1.01
28
807
47
1120
0.36
10.66
2.1
2.9
—
—
estimate
—
0
0
23
791
0.26
10.54
5.2
3.7
6.33
13.85
mg/mmol
1.76
12
522
66
1348
0.41
10.45
3.2
4.1
31.87
32.97
g/l
0.57
51
1227
108
1808
0.49
9.84
5.0
5.6
—
3.60
—
0
5
29
847
0.30
9.83
2.0
2.5
—
—
—
0
0
26
802
0.29
9.75
4.0
4.5
—
—
—
0
0
23
742
0.28
9.32
3.4
3.0
6.50
6.15
mmol/l
0.27
16
598
24
750
0.29
9.16
3.3
2.9
92.82
70.94
mg/l
0.17
13
515
41
979
0.37
9.14
2.2
2.5
2.78
3.33
mg/l
1.26
30
835
151
2239
0.54
9.10
16.2
21.4
—
—
—
0
0
104
1702
0.51
8.48
18.3
28.4
14.31
14.48
%
0.63
94
1666
44
985
0.40
8.38
2.6
2.8
2.37
2.35
mmol/l
0.54
31
876
22
686
0.29
8.31
7.0
6.0
—
—
—
0
0
50
1055
0.42
8.24
3.8
4.1
60.64
138.75
e6/l
0.57
39
859
37
887
0.37
8.22
1.5
2.7
—
—
—
0
0
21
659
0.29
8.00
2.1
2.8
390.62
392.51
umol/l
0.02
13
544
38
889
0.38
7.96
3.9
3.6
7.40
7.40
ph
0.52
30
658
12
514
0.22
7.73
2.3
2.5
23.00
19.66
%
—
7
474
43
937
0.41
7.59
2.1
2.0
347.84
270.59
u/l
0.30
31
872
171
2368
0.58
7.43
20.3
33.7
123.33
124.16
g/l
0.27
152
2309
41
904
0.41
7.43
3.6
4.0
0.78
0.58
e6/l
0.31
33
734
171
2367
0.59
7.41
19.9
33.3
30.43
30.28
pg
0.36
152
2301
171
2367
0.59
7.41
20.1
33.8
36.65
36.89
%
0.15
151
2298
171
2367
0.59
7.41
19.9
33.4
4.08
4.14
e12/l
0.70
150
2276
171
2367
0.59
7.41
19.9
33.4
92.32
92.13
fl
0.15
152
2301
171
2367
0.59
7.41
19.8
33.4
239.07
231.63
e9/l
0.64
149
2285
16
561
0.26
7.40
1.9
2.4
2.23
2.16
g/l
—
9
508
171
2361
0.59
7.29
16.8
28.7
140.08
139.10
mmol/l
2.34
151
2280
171
2361
0.59
7.29
16.9
28.9
4.05
4.06
mmol/l
0.10
151
2280
173
2367
0.60
7.00
17.5
30.8
90.72
95.48
umol/l
1.15
152
2291
40
869
0.42
6.95
3.2
6.2
27.30
10.66
ug/l
0.35
35
752
11
460
0.22
6.80
1.9
1.8
30.71
29.87
s
0.32
11
445
168
2304
0.60
6.78
15.5
23.2
40.28
31.52
mg/l
1.28
138
2065
175
2370
0.60
6.66
19.7
33.4
7.87
7.48
e9/l
0.90
153
2274
106
1633
0.56
6.62
19.3
25.2
1.61
1.53
inr
0.62
91
1436
27
679
0.36
6.54
3.3
3.0
2.50
2.48
mmol/l
0.34
17
584
38
824
0.42
6.53
3.7
4.1
—
0.00
estimate
—
0
12
62
1121
0.49
6.51
3.8
4.7
64.79
261.83
e6/l
2.32
39
885
114
1712
0.57
6.44
17.6
30.3
328.68
328.21
g/l
0.21
105
1674
26
649
0.37
6.18
4.1
4.7
170.40
169.52
ng/l
0.00
21
607
14
468
0.28
5.92
2.6
3.9
—
—
—
0
0
7
296
0.23
5.78
1.1
2.1
63.14
64.94
g/l
—
7
261
43
835
0.47
5.45
3.0
2.4
50.87
63.09
u/l
1.11
38
764
8
304
0.25
5.42
1.1
1.5
—
—
—
0
0
86
1342
0.57
5.39
4.8
5.4
0.00
0.00
estimate
-0.00
18
350
78
1238
0.56
5.17
3.7
4.4
—
—
—
0
0
0
128
0.00
5.16
0.0
1.6
—
—
—
0
0
12
404
0.28
5.14
1.6
4.5
4.17
1.32
mmol/l
—
6
304
8
293
0.26
5.12
1.5
4.5
1.64
1.52
mmol/l
—
8
282
22
539
0.38
4.98
1.3
1.6
1.07
1.62
mg/l
1.33
17
433
89
1348
0.59
4.90
3.9
5.1
51.20
109.83
ng/l
0.71
61
1123
40
769
0.48
4.89
4.7
3.6
549.60
516.48
mosm/kgh2o
0.85
35
676
38
742
0.47
4.86
1.9
1.8
435.83
453.20
pmol/l
0.15
23
590
87
1320
0.59
4.81
4.8
5.4
0.00
0.00
estimate
-0.00
18
342
6
249
0.23
4.76
1.0
2.0
—
—
—
0
0
89
1336
0.60
4.69
4.7
5.4
0.00
4.45
estimate
0.50
20
365
8
281
0.27
4.68
1.3
1.3
—
—
—
0
0
68
1089
0.57
4.58
3.2
4.5
—
—
—
0
0
20
492
0.38
4.57
2.9
3.6
2.97
2.19
e6/l
0.36
15
273
20
489
0.39
4.51
1.2
1.3
—
—
—
0
0
5
217
0.22
4.20
1.2
1.4
—
—
—
0
0
74
1070
0.64
3.16
4.6
4.7
6.43
6.39
ph
0.09
47
597
50
789
0.59
3.10
2.1
1.8
1353.63
1146.82
nmol/l
0.59
30
591
8
224
0.35
3.00
1.5
1.9
0.18
0.17
g/l
—
8
194
0
80
0.00
2.94
0.0
1.3
—
55.25
—
0
61
6
189
0.31
2.86
1.8
1.3
—
—
—
0
0
22
425
0.50
2.73
2.2
3.8
—
—
—
0
0
11
276
0.39
2.68
3.5
2.6
0.14
1.05
e6/l
1.72
11
265
0
70
0.00
2.61
0.0
1.3
—
262.31
—
0
63
6
174
0.34
2.45
2.3
6.3
93.25
93.84
%
—
6
174
17
344
0.48
2.43
2.1
2.7
15.03
6.14
ug/l
—
10
273
24
433
0.53
2.42
1.5
1.9
—
—
—
0
0
7
184
0.37
2.33
2.3
2.8
—
—
—
0
0
0
61
0.00
2.25
0.0
1.1
—
—
—
0
0
5
149
0.33
2.18
1.0
1.3
—
—
—
0
0
5
151
0.32
2.18
1.6
2.1
—
—
—
0
0
0
55
0.00
2.08
0.0
1.3
—
—
—
0
0
79
1035
0.72
1.94
4.9
5.7
0.00
0.10
estimate
2.79
14
283
5
142
0.35
1.90
2.0
3.2
—
—
—
0
0
0
51
0.00
1.89
0.0
1.3
—
8.64
—
0
10
0
53
0.00
1.88
0.0
1.0
—
—
—
0
0
6
152
0.39
1.79
2.2
4.3
—
—
—
0
0
5
136
0.36
1.78
1.0
1.3
—
—
—
0
0
61
806
0.72
1.58
5.0
5.1
0.00
0.01
estimate
0.50
15
282
0
44
0.00
1.52
0.0
1.2
—
3.54
—
0
5
13
239
0.53
1.46
1.2
3.0
104.60
102.33
ng/l
—
5
199
5
16
3.14
1.44
1.2
1.1
—
—
—
0
0
9
179
0.49
1.42
1.3
1.2
—
—
—
0
0
22
347
0.62
1.41
1.5
1.9
—
—
—
0
0
5
120
0.41
1.39
1.0
1.3
—
—
—
0
0
14
239
0.57
1.24
1.7
3.0
—
—
—
0
0
57
726
0.76
1.17
4.3
5.1
0.00
0.03
estimate
1.23
15
248
0
34
0.00
1.16
0.0
2.4
—
—
—
0
0
0
34
0.00
1.16
0.0
1.6
—
8.00
—
0
34
0
35
0.00
1.15
0.0
1.1
—
32.94
—
0
30
5
108
0.46
1.02
1.0
1.1
—
—
—
0
0
0
29
0.00
0.98
0.0
3.8
—
28.49
—
0
24
0
30
0.00
0.97
0.0
2.5
—
59.46
—
0
25
0
32
0.00
0.95
0.0
1.7
—
14.09
—
0
32
48
603
0.78
0.91
4.5
5.8
1.02
1.02
kg/l
0.05
31
408
0
24
0.00
0.79
0.0
1.3
—
—
—
0
0
0
24
0.00
0.79
0.0
1.3
—
—
—
0
0
0
24
0.00
0.79
0.0
1.3
—
—
—
0
0
0
24
0.00
0.79
0.0
1.3
—
—
—
0
0
0
27
0.00
0.77
0.0
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
1.1
—
—
—
0
0
10
158
0.63
0.71
6.8
5.4
—
—
—
0
0
7
42
1.68
0.68
3.1
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.7
—
9.30
—
0
22
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
9.89
—
0
9
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
6.15
—
0
16
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
3.71
—
0
18
5
77
0.65
0.36
1.0
1.2
—
—
—
0
0
9
126
0.71
0.35
1.2
1.3
—
—
—
0
0
5
39
1.28
0.23
1.0
1.3
—
—
—
0
0
5
41
1.22
0.22
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
68.17
—
0
6
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
5.40
—
0
5
0
11
0.00
0.21
0.0
6.1
—
8.05
—
0
11
0
11
0.00
0.21
0.0
1.3
—
1.18
—
0
11
0
11
0.00
0.21
0.0
2.2
—
0.87
—
0
11
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
327.25
—
0
12
0
12
0.00
0.21
0.0
1.0
—
43.40
—
0
5
0
12
0.00
0.21
0.0
2.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
81.92
—
0
13
0
14
0.00
0.20
0.0
1.4
—
45.39
—
0
14
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
6
49
1.23
0.20
2.2
2.9
11.57
14.74
pmol/l
—
6
49
22
226
0.97
0.00
4.9
5.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
48.54
—
0
8
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
9
92
0.98
0.00
3.1
5.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
7.87
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
120.17
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.06
—
0
5
0
7
0.00
-0.00
0.0
1.6
—
79.86
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
4.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
0.57
—
0
6
6
63
0.95
-0.00
1.7
1.6
10719.67
22676.14
e6/l
—
6
44
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
43.14
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
2.16
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
8.0
—
72.32
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
190.40
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
25.00
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
51
0.98
-0.00
4.2
2.6
72.00
62.84
%
—
5
51
0
7
0.00
-0.00
0.0
1.6
—
100.57
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
111.57
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: AD_U – Alzheimer’s disease (undefined)

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).